Journal of Sports Medicine

Journal of Sports Medicine / 2018 / Article

Review Article | Open Access

Volume 2018 |Article ID 5724575 |

Lawrence E. Armstrong, Elaine C. Lee, Elizabeth M. Armstrong, "Interactions of Gut Microbiota, Endotoxemia, Immune Function, and Diet in Exertional Heatstroke", Journal of Sports Medicine, vol. 2018, Article ID 5724575, 33 pages, 2018.

Interactions of Gut Microbiota, Endotoxemia, Immune Function, and Diet in Exertional Heatstroke

Academic Editor: Richard Davison
Received21 Aug 2017
Accepted03 Jan 2018
Published16 Apr 2018


Exertional heatstroke (EHS) is a medical emergency that cannot be predicted, requires immediate whole-body cooling to reduce elevated internal body temperature, and is influenced by numerous host and environmental factors. Widely accepted predisposing factors (PDF) include prolonged or intense exercise, lack of heat acclimatization, sleep deprivation, dehydration, diet, alcohol abuse, drug use, chronic inflammation, febrile illness, older age, and nonsteroidal anti-inflammatory drug use. The present review links these factors to the human intestinal microbiota (IM) and diet, which previously have not been appreciated as PDF. This review also describes plausible mechanisms by which these PDF lead to EHS: endotoxemia resulting from elevated plasma lipopolysaccharide (i.e., a structural component of the outer membrane of Gram-negative bacteria) and tissue injury from oxygen free radicals. We propose that recognizing the lifestyle and host factors which are influenced by intestine-microbial interactions, and modifying habitual dietary patterns to alter the IM ecosystem, will encourage efficient immune function, optimize the intestinal epithelial barrier, and reduce EHS morbidity and mortality.

1. Introduction

Exertional heatstroke (EHS), resulting from prolonged exercise-induced hyperthermia, is one of the few disorders that disables young, healthy, physically fit individuals [1]. When the metabolic heat produced by muscle during exercise or labor exceeds body heat dissipation to the surrounding environment, internal body temperature rises to a level that disrupts organ function. Clinically, EHS is a medical emergency defined by hyperthermia (internal body temperature > 40°C) associated with central nervous system and multiple-organ dysfunction; thus, EHS is distinguished from other exertional heat illnesses (e.g., exertional heat exhaustion, heat syncope, and heat cramps) and from the physiological responses which result from exercise-heat stress (i.e., heat strain) [2, 3]. Although numerous PDF for EHS have been described (Table 1), they all potentiate hyperthermia in deep body tissues [1, 4]. In a report regarding EHS in a large military cohort, Abriat et al. [5] stated, “…determination of the factors contributing to [EHS] recurrence is urgently needed….” This call for action arose from their observation that 15% of EHS patients experienced a similar event at a later date. Equally troubling data were published by Leon and Helwig [6] regarding longevity of former military EHS patients. When compared to patients with a non-heat-related illness, former EHS patients had double the mortality from cardiovascular, kidney, and liver failure within 30 years of hospitalization. Unfortunately, the cause(s) of recurrent EHS and increased morbidity and mortality are unknown.

Hot, humid environment with direct solar radiation and little wind movement
Insulated clothing
Low ratio of skin surface area to body mass
Recent (1–3 days) stressful heat exposure
Lack of heat acclimatization
Medications that alter sweat gland function, cutaneous vasoconstriction, or cardiac contractility
Skin disorders (e.g., ectodermal dysplasia, burns, anhidrosis)
Strenuous or prolonged exercise
Overweight, obesity
Diarrhea, vomiting
Use of diuretics and laxatives
Fever and illness
Infectious disease
Low cardiorespiratory physical fitness
Alcohol abuse or drug use
Older age
Sleep deprivation

Sources. [13, 50, 164, 322].

EHS cannot be predicted and often strikes athletes, laborers, and soldiers during activities that they have performed previously, in similar environmental conditions, at the same exercise intensity-duration, and while wearing similar clothing/gear. Thus understanding the predisposing factors (PDF) for EHS, and taking proactive measures to counteract those factors, reduces the risk of injury or death. Previously, members of our laboratory proposed the intestinal microbiota (IM) as a predisposing factor that deserves greater consideration in the etiology of EHS [7]. The present article again proposes the IM as a key factor in the etiology of EHS but further describes the interactions of the IM with intestinal ultrastructure, gut physiological functions, the immune system, illness, diet, exercise, and personal characteristics. The role of endotoxemia is emphasized. This article also recommends steps to reduce EHS morbidity and mortality by encouraging efficient metabolic and immune system function.

2. Characteristics of the IM

Population studies indicate that 300–500 different species of bacteria constitute the majority of microorganisms in the human gut [8]. When rare, low-abundance, uncultivated or unclassified bacteria are considered, the healthy human gut likely contains more than 1000 species [9]. The Bacteroidetes (genera Bacteroides and Prevotella) and the Firmicutes (genera Clostridium, Eubacterium, and Ruminococcus) (Figure 1; Table 2) account for more than 90% of the IM population [10, 11]. Although the exact mechanisms and scope of influence are unknown, primarily because this ecosystem remains incompletely characterized and its diversity poorly defined, the human IM apparently exerts a broad range of health-related effects [12]. These include intestinal development during infancy and malnutrition, allergies, appetite control, energy balance, and pathology, or prevention of metabolic diseases such as obesity, diabetes, inflammatory bowel diseases, neurological disorders, cancers, and cardiovascular diseases [10, 1214]. The IM also has been implicated in the development of central and peripheral neural processes (i.e., the brain-gut-enteric microbiota axis), as well as the central response to stress via the hypothalamic-pituitary-adrenal axis [11]. These wide ranging effects on human health have prompted many investigators to consider the role of IM diversity. Individuals with a greater IM species diversity apparently have a greater repertoire of microbial metabolic functions (Figure 2), a gut microbiome which is more functionally robust and which theoretically allows them to cope with homeostatic disruptions more effectively than individuals with less IM species diversity [9, 15]. For example, greater bacterial diversity was shown to correspond with better nutritional status, fewer comorbidities, and greater overall health in a cohort of elderly individuals [16]. Thus, it is generally agreed upon that the characteristics of a healthy microbiota include community stability and increased species diversity [17]. Theoretically, greater IM diversity provides the host with a wider repertoire of bacterial processes (i.e., metabolism, nutrient transport, energy production, cell signaling, reproduction, and growth) to maintain IM homeostasis and health (Figure 2).

Intestinal segmentPredominant bacterial Bacterial metabolismPotential biological functions of bacteria metabolites
Biochemical Metabolic intermediates &  

 Small intestine



Resistant starches, dietary fiber (cellulose, pectin, inulin), carbohydrates, amino acids, lipids, triglycerides, carboxylic acids, creatine, pancreatic/gastrointestinal secretions, and mucus.

Complex carbohydrates, amino acids, lactic acid, ethanol, succinic acid, and formate produce short-chain fatty acids (SCFA; acetate, propionate, butyrate), branched-chain fatty acids (BCFA), CO2, H2, NH3, H2S, amines, phenols, biotin, and vitamins K, B1, B2, B6, B12.
Absorb fats and lipid-soluble vitamins, stimulate systemic hormones to regulate lipid and glucose homeostasis, energy regulation, modulate pro- and anti-inflammatory genes, strengthen epithelial permeability, regulate colon pH, inhibit pathogen growth, provide energy to luminal epithelium.

Large intestine

Bacteroidetes, Firmicutes, Proteobacteria

Notes. Inter-individual differences are great; composition of substrates, intermediates and products change along the course of the intestinal tract; the outer membrane of Proteobacteria is composed mostly of LPS; most SCFA exist in higher concentrations in the proximal (versus distal) colon; phyla differ markedly in proximal versus distal colon, in part due to differences in oxygen tension. Abbreviations: IM, intestinal microbiota; LPS, lipopolysaccharide. Sources: [135, 152, 154, 253, 319, 323327].

3. Diet and Exercise Alter IM Abundance and Diversity

Specific microbe classes (i.e., which enhance metabolism, resilience to infection/inflammation, resistance to autoimmunity, and endocrine signaling) have been considered to be important in human health. Examples of bacterial taxa that have been associated with health and effective gastrointestinal function include Bacteroides, Bifidobacterium, Eubacterium, Faecalibacterium, Lactobacillus, and Roseburia [15]. However, multiple factors can alter the ratio of bacterial families across time, including disease and diet [13]. For example, the ratio of two major genera of gut bacteria, Prevotella and Bacteroides, were different in a community that consumed a high-fiber diet (e.g., Africa, Malawi, and Venezuela) dominated by maize, cassava, and other plant polysaccharides, versus one that consumed a diet rich in animal protein and saturated fats (e.g., USA and Europe). Also, as part of a dietary intervention study, Russell and colleagues [18] provided 17 obese men with a controlled weight-maintenance diet for 7 days. Subsequently, for 4 weeks each, these men consumed a high-protein and moderate-carbohydrate diet (HPMC; 139 g protein, 82 g fat, and 181 g carbohydrate/d) and a high-protein and low-carbohydrate (HPLC; 137 g protein, 143 g fat, and 22 g carbohydrate/d) diet, as part of a crossover experimental design. With the HPLC diet, the Roseburia/Eubacterium rectale group, an abundant Gram-positive family Lachnospiraceae, decreased () as a proportion of total bacteria. While consuming the HPLC diet, the proportion of Bacteroides spp. decreased by 22% (), relative to the maintenance diet. In yet another study, utilizing a rat model of anorexia, researchers employed extreme food restriction plus increased activity; this combination of factors negatively impacted the quantity of health-promoting bacteria and enhanced the growth of bacteria which may be related to disruption of the gut mucosal barrier. Specifically, a significant increase was observed in the number of Proteobacteria, Bacteroides, Clostridium, Enterococcus, Prevotella, and M. smithii and a significant decrease in the quantities of Actinobacteria, Firmicutes, Bacteroidetes, B. coccoides-E. rectale group, Lactobacillus, and Bifidobacterium [19]. Further, excessive nutrient loading of the IM, or consuming a diet that eliminates one or more essential nutrients, may lead to an altered IM diversity because a small number of species overgrow and outcompete other flora (Figure 1). Consistent with this concept, decreased IM diversity has been linked with a diet that is high in fat and sugar, compared to a low-fat plant-based diet [20, 21].

Focusing on IM diversity, a study of elite Irish professional rugby players (; age,  y; body mass index, ) evaluated the impact of exercise and dietary changes during preseason training. Investigators [22] performed a high-throughput DNA sequencing analysis of fecal microbiota with concurrent measurements of proinflammatory cytokines and metabolic health. Gut microbiota diversity was significantly greater in the athletes compared with size matched (body mass index > 28, ) and age/gender matched BMI ≤ 25 control groups, with few differences seen between the two control cohorts. Athletes also had lower inflammatory responses and improved metabolic markers of health than the high BMI control group. Athletes consumed significantly more calories, protein, fat, and carbohydrate per day than both control groups. Microbiota diversity measures positively correlated with protein intake and plasma creatine kinase levels (a marker of extreme exercise), which suggested that both diet and exercise influenced the changes of microbial diversity [23]. Similarly, three investigations have shown that exercise training (20–66 min/d, 5 d/wk, 4–6 wk) alters the IM of rats [24], including pregnant and diabetic animals. Danish scientists at the University of Copenhagen [25] examined the impact of exercise training on the ability of exogenous i.v. lipopolysaccharide (LPS) to induce an inflammatory response (i.e., TNF-α, IL-6) in plasma and in biopsied skeletal muscle and adipose tissues of healthy young men. This research group reported that physical training status affected the ability to induce an acute inflammatory response, in a tissue-specific manner. In support of the above research, Campbell and Wisniewski [17] reviewed relevant publications and concluded that physical exercise training (a) is a potent intervention for the restoration of metabolic and gut health (i.e., subsequent to metabolic syndrome or gut inflammation), as well as for the diversification of the gut microbiota; (b) increases microbial diversity independent of diet; (c) increases antioxidant enzymes and anti-inflammatory cytokines; and (d) decreases proinflammatory cytokines [17]. These responses and adaptations explain, in part, why a program of regular physical exercise represents a cornerstone in the primary prevention of at least 35 chronic diseases [26].

4. The IM as a Predisposing Factor for EHS

The human IM is a community of commensal, symbiotic, and pathogenic microorganisms that reside within the human body in a complex bionetwork containing approximately 1013 cells. These microorganisms exceed the number of cells in the entire human body by a factor of 10 and their number of genes by a factor of 100. The IM may have a biomass as large as 2 kg, along the course of an 8 m intestine [27]. The total count of bacteria increases, moving from proximal to distal sites (Table 3): stomach, 0–103; jejunum, 0–103; ileum, 103–107; colon, 109–1012; and feces, [28]. Bacteria in the mammalian intestine produce and detect numerous extracellular signaling molecules, as one component in the multiple layers of communication between the IM, the host, and incoming pathogens [11]. For example, the gut IM constantly interacts with the host immune system and intestinal ultrastructure [29] (Table 4). Lipopolysaccharide (LPS), which originates from the outer membrane of Gram-negative bacteria, peptidoglycans, and bacterial DNA are recognized by receptors on luminal and intestinal immune cells [30]. Also, evidence demonstrates that commensal bacteria can communicate with incoming pathogens, control the expression of virulence, and inhibit the production of toxins [11]. Indeed, some of the signaling molecules which are sensed by incoming pathogens and which affect their function also may be produced by other pathogens.

Intestine segmentIntestine functionsIntestine anatomy, circulation, and environmentBacterial characteristicsMicrobe load per g of luminal contents

Small intestine (1–3 cm diameter; length, duodenum 0.4 m, jejunum 2.5 m, ileum 3.5 m)Absorbs > 95% of essential dietary nutrients (e.g., water, ions, amino acids, peptides, glucose, fructose, lipids, iron, vitamins). Peristalsis mixes and moves chyme distally. Secretions neutralize stomach acid and chemically digest food (e.g., bile salts). Endocrine feedback blocks stomach acid production and stimulates pancreatic insulin secretion. Supports local immunity against pathogens.Surface of the luminal epithelium is covered with microvilli, which contain digestive enzymes and membrane nutrient transporters. Aerobic environment with pH of 6-7. Partial pressure of oxygen (pO2) in terminal ileum tissue, 33 mmHg.
Blood supplied by superior mesenteric artery. At rest, intestinal capillaries receive ~20% of total cardiac output, but ~75% of these capillaries are not perfused when unfed (i.e., without glucose or other nutrients).
Aerobic species and facultative anaerobes (with bimodal metabolism) predominate. Gene activity analysis indicates: amino acids > carbohydrates > cofactors/vitamins > lipid metabolism.Duodenum and jejunum, <103; Ileum, 103–107.

Large intestine (6 cm diameter; length, cecum 0.2 m, colon 1.4 m, rectum 0.1 m)Absorbs unabsorbed water and vitamins. Secretions neutralize acidic pH. Compacts waste for elimination. Rectum stores feces temporarily. Supports local immunity against pathogens.Microvilli are absent. Anaerobic environment (pO2 of sigmoid colon tissue, 3 mmHg; rectum, <1 mm Hg) with a pH of 5–7. The lumen center has a pO2 < 0.1 mmHg.Caecum has greatest diversity (500–1,000 species); facultative anaerobes dominate. Distal colon has smallest species diversity; obligate anaerobes dominate.Colon, 109–1012; Feces, 1010–1012

Facultative anaerobes grow with or without oxygen; obligate anaerobes grow only in the complete absence of oxygen and process substrates via fermentation; both Gram-positive and Gram-negative bacteria populate the small and large intestine segments. Sources: [152, 259, 325, 328330].

Intestinal lumen sites/processesBacterial effects on immune functionInfluence of diet

Mucus layer(i)  Block cell adhesion sites of pathogenic bacteria 
(ii) Site of competition for nutrients with pathogenic bacteria X
(iii) Affect function of mucosal immune cells/factorsX
(iv) Alter bacterial diversity and abundance of specific phylaX

Epithelial cell layer(i)  Goblet cells secrete mucins (high molecular weight glycoproteins) which prevent entry of pathogens and noxious substances 
(ii) Paneth cells contain antimicrobial peptides 
(iii) Express heat shock proteins which reduce inflammation and injuryX
(iv) Influence the function of lymphocytes, leukocytes (T-cells, macrophages, secretory immunoglobulin A), neutrophils, monocytesX

Biochemical/metabolic processes(i)  Produce antimicrobial substances that inhibit pathogenic bacteria    
(ii) Produce LPS, which affects systemic, liver, adipose tissue inflammation X 
(iii) Modulate antibody production in response to large antigen load X 
(iv) Degrade toxins and toxin receptors 
(v) Bacterial metabolites (e.g., SCFA) have pro- and anti-inflammatory effectsX

Due to its vast surface area, the human intestine houses the largest number of immune cells in the human body. Mucus layer is the first line of defense against physical and chemical injury caused by ingested food, microbes, and microbial products; heat shock protein expression increases. IM, intestinal microbiota; LPS, lipopolysaccharide, an endotoxin; SCFA, short-chain fatty acids. Sources: [52, 103, 130, 133, 154, 316, 327, 330333].

The mucosal lining of the gastrointestinal tract protects the internal environment of the body from bacteria and endotoxins such as LPS [31]. This barrier consists of physical factors (i.e., enterocyte membranes and tight junctions), mucous secretion, and immune factors [31, 32]. Although a small amount of gastrointestinal permeability is normal, a healthy immune system prevents adverse effects; low levels of endotoxin are rapidly removed by monocytes, in particular the Kupffer cells that reside in liver tissues [33]. Dysfunction of or damage to the mucosal lining, and the adjoining single layer of epithelial cells, leads to increased permeability (i.e., diffusion of molecules from the lumen into blood) with mitochondrial swelling and vacuolization ([32]; Figure 3). Increased gastrointestinal permeability (i.e., barrier dysfunction) is of concern because it may allow passage of harmful substances (e.g., endotoxin, food antigens, digestive enzymes, and bile) from the intestinal lumen into blood. This can create local and/or systemic inflammation and endotoxemia. The latter is widely believed to be an etiological factor in EHS and its outcome [34].

The means by which LPS stimulates a proinflammatory immune response is well-described. The factors which have not yet been considered in the role of LPS-induced immune response and EHS pathophysiology are as follows: (1) the diversity of both immune responses to LPS and ligands that may stimulate the LPS responsive receptor on immune cells known as TLR-4 (toll-like receptor-4), (2) the diversity of LPS structural variants that can stimulate different immune responses, and (3) other endogenous molecules that can affect how LPS stimulates proinflammatory responses. Intriguingly, all three of these components have not yet been considered in published work on EHS pathophysiology.

LPS is recognized by a cell membrane receptor named TLR-4 on immune cells (Figure 4). When TLR-4 is bound by LPS and other accessory proteins (e.g., lymphocyte antigen protein 96 termed MD-2) the complex stimulates intracellular communication by multiple pathways that converge when different proteins enter the nucleus and change gene expression, to stimulate production of proinflammatory proteins that may be released into circulation or signal to the immune system in other ways. Much of the work on endotoxemia and sepsis in EHS pathophysiology has focused on LPS. However, there are multiple ligands (i.e., molecules that can bind to TLR-4) in addition to LPS that can stimulate TLR-4 to produce the same or an augmented proinflammatory response. A 2010 review [35] described over 20 endogenous or naturally occurring (versus synthetic or pharmacological) TLR-4 ligands that are capable of stimulating proinflammatory processes; this review emphasized concerns regarding contamination of experimental systems by these ligands. Thus, the mechanistic diversity of TLR-4 stimulation should be considered in hypotheses regarding endotoxemia/sepsis and EHS. For example, heat shock protein 60 (HSP60), a protein that increases with exercise [36], is also considered to be, in its protective role, a DAMP (i.e., danger-associated molecular pattern). In this role, HSP60 is able to bind to receptors like TLR-4 on immune cells to stimulate an immune response. It is likely that signals from LPS, DAMPs like HSP60, and other TLR-4 ligands can concurrently magnify the proinflammatory response to exercise-heat stress and associated tissue damage during EHS.

Another consideration that can affect how LPS may play a role in EHS is the diversity of the LPS molecule itself. LPS is made of 3 domains including a core of oligosaccharides bound to molecules termed the Lipid A anchor and the O antigen. Lipid A is known to be the primary component of LPS that stimulates the immune response resulting in endotoxemia and sepsis. Both the degree of molecular modifications of Lipid A and genetic differences in the TLR-4 protein receptor among individuals can have a notable impact on LPS responsiveness and the strength of a proinflammatory response [37]. Variations in Lipid A that arise from different bacterial species can also affect how TLR-4 recognizes LPS and how potently it stimulates a proinflammatory response [38]. These potential variations in Lipid A and TLR-4 structure have not yet been studied in the hypothetical role of the IM in EHS pathophysiology.

A third major consideration involves the variation of ligands that directly bind TLR-4 and the diversity of molecules that can independently affect TLR-4 stimulation of an immune response; some of these can be produced in and leaked from the gut. One highly intriguing example is that of oleoylethanolamide (OEA), a small molecule produced in the small intestine. Experiments have demonstrated that OEA can directly inhibit LPS-induced TLR-4 stimulation of the immune response by defined mechanisms [39]. Treatment of human cells with OEA has prevented full gene expression associated with LPS-induced stimulation of TLR-4 and has significantly reduced proinflammatory signaling. Thus, it is evident that there may be multiple inputs to regulate the immune responses which occur during exercise-heat stress, to either promote or inhibit the progression of EHS.

Table 4 describes influences which the IM may have on immune function and inflammation [40]. These effects include degradation of toxins produced by pathogenic bacteria, modulation of antibody production in response to antigens, production of metabolites which have proinflammatory and anti-inflammatory actions, and release of LPS from the wall of Gram-negative bacteria when they die. Importantly, Table 5 notes that LPS in plasma is a potent agonist for the release of proinflammatory cytokines during EHS. In severe EHS cases, multiple-organ dysfunction or failure occurs, mediated by leakage of LPS into the circulation [4143]; this may culminate in systemic hypotension and cardiovascular shock [4447]. In dogs, intravenous injection of Escherichia coli endotoxin is characterized by an immediate, rapid decline of blood pressure with a simultaneous elevation of hepatic portal vein pressure, signifying trapping of blood in the liver [48]. The combined effects of LPS and hyperthermia also stimulate blood coagulation. Autopsy findings typically include hemorrhage and microthromboses in the splanchnic organs, (i.e., intestine, liver, lungs, kidneys, pancreas, and spleen), heart, brain, cornea, and skin [43, 4951].

Hypothetical involvement in EHS

Intestine anatomy & physiology(i)  Gut anatomy (i.e., crypts) and the surrounding mucus layer facilitate immune homeostasis, protects commensal species from bacterial competitors, and reseeds the IM after the ecosystem has been altered/depleted [331, 334].
(ii)  Epithelial membrane integral proteins (i.e., toll-like receptors) recognize bacteria and other microorganisms. Once activated, these receptors can recruit immune cells and produce cytokines, which in turn regulates the number and diversity of bacteria in the gut [335].
(iii) Disruption of normal bowel function as a result of infection or inflammation uncovers its critical importance for acid-base homeostasis and normal mucosal pH [336].
(iv) Hyperthermia damages membranes of intestinal epithelial cells [31], disrupts tight junctions [337], and increases permeability to LPS [32, 101]. This permeability change occurs at temperatures of 41.5–42.0°C when sustained for 60 min [31].
(v) Human nonexertional heatstroke patients (mean rectal temperature, 42.1°C) exhibit increased plasma LPS [68, 69].
(vi) The epithelial mucosa becomes acidic during intense, anaerobic exercise [73, 88, 180, 338].
(vii) Hypoxia in the intestinal mucosa releases highly reactive oxygen and nitrogen species that accelerate mucosal injury [45, 339]; similar hypoxia-induced production of ROS and RNS occurs in liver cells [44].

Bacteria(i)  Products of bacterial metabolism (a) increase intestinal permeability and plasma LPS concentration, (b) strengthen the epithelial cell barrier, and (c) modulate expression of both proinflammatory and anti-inflammatory genes [135]. Bacterial metabolic products influence both innate and adaptive immune cell functions [340].
(ii) Commensal bacteria produce short-chain fatty acids (which have anti-inflammatory properties in multiple immune cell types); they also synthesize vitamins and amino acids which influence immune function [130, 135].
(iii) In patients with chronic inflammatory bowel diseases (e.g., Crohn’s disease, ulcerative colitis) and alcoholic liver disease, the IM differs from control subjects, and plasma LPS is chronically elevated [152, 155, 244, 330].
(iv) An array of diseases and dysfunctions (e.g., atherosclerosis, burn injury) have been hypothetically associated with an imbalance of the composition, numbers, or habitat of the IM [11, 154, 330].
(v) Several bacterial activities have been linked to increased risk of gastric and colorectal cancer [154, 330].

Immune function(i)  The IM can modulate innate and adaptive immune responses at mucosal surfaces during infection, inflammation, and autoimmunity [170].
(ii) Changes in the crosstalk between the intestinal epithelium, the intestinal immune system, and gut microbes modulate systemic immunity [335].
(iii) LPS is released upon the death of Gram-negative bacteria. LPS is a potent stimulus for the release of cytokines. The resulting inflammatory response can alter thermoregulation and result in multiple-organ dysfunction [42]. LPS can cause death at plasma concentrations as low as 1 ng/mL [43].
(iv) Proinflammatory (TNF-α, IL-1β) and anti-inflammatory (IL-6, IL-10) cytokine concentrations in plasma are elevated during exercise-induced hyperthermia and exertional heatstroke [44].
(v) Severe EHS victims may succumb to a condition similar to sepsis [4143], mediated by leakage of LPS from the intestinal lumen into the circulation. This leads to an immune (i.e., cytokine) inflammatory response culminating in systemic hypotension, cardiovascular shock, and multiple organ failure [4446]. EHS fatalities among primates exhibit greater coagulopathy, inflammation, and tissue injury than hyperthermic survivors [42].
(vi) LPS also stimulates blood coagulation; thus EHS-induced microthrombosis and hemorrhage occur in tissues of the intestine, liver, lungs, kidneys, pancreas, spleen, skin, cornea, heart, brain, and adrenals [43, 4951].
(vii) Administration of immunomodulators, antibodies to endotoxin, and corticosteroids improve survival in animals with heatstroke and attenuate hemodynamic instability, but have not been studied in humans [44].
(viii) At rest, pre-hydration with an intravenous glucose-NaCl solution shifts cytokine (TNF-α, IL-1β, IL-8) responses to injected human endotoxin towards a more anti-inflammatory balance [123].

Diet(i)  Diet modulates inflammation and immune function at rest [103, 133] 
(ii) At rest, diet modulates the pH of colon mucosa, intestinal permeability, as well as glucose, insulin, and energy metabolism [135].
(iii) A change of diet rapidly alters IM composition [253, 256].
(iv) A high-fat, low-fiber Western diet promotes the overgrowth of gram-negative pathogens, with consequent increased intestinal translocation of bacterial LPS [153].
(v) Obesity and Type 2 diabetes are associated with a chronic low-grade inflammatory state, known as “metabolic endotoxemia” [341, 342] because these diseases involve translocation of LPS from the intestinal lumen into blood. Extensive research involving mice demonstrated that a 4-week high-fat diet chronically increased plasma LPS levels [153], and induced obesity and insulin resistance. Altering the IM of mice by antibiotic administration protected mice from fat mass development, glucose intolerance, insulin resistance, mild endotoxemia, inflammation [136].
(vi) Metabolic endotoxemia (interrelationships between LPS, a high-fat diet, obesity, and Type 2 diabetes) has been confirmed in multiple studies involving healthy and obese humans (publications reviewed by [40]).

Exercise stress (intensity & duration)(i)  Numerous studies have reported lower splanchnic and mesenteric blood flows during strenuous exercise; this can result in hypoxia, intestinal barrier disruption [34, 122, 180, 343]. This hypoxic state, evident in the intestinal villi and lobes of the liver, likely results in ATP depletion, acidosis, and altered membrane ion pump activity [43, 51, 339, 344].
(ii) EHS and non-exertional (classical) heatstroke often involve systemic acidosis [51, 345, 346].
(iii) During high intensity (80%  ; [87]) and prolonged (>9 h; [84, 86]) exercise, the incidence of endotoxemia (plasma LPS) increases.
(iv) Exercise-induced (running 60 min at 70%  ) mild dehydration (−1.5% body mass loss) increases intestinal permeability [122].
(v) Efficient energy metabolism (i.e., biochemical generation of ATP) is essential during prolonged or intense exercise. Bacteria may influence energy metabolism by modulating intestinal transit time (energy harvest); polysaccharide degradation to monosaccharides; glucose absorption into intestinal epithelial cells; de novo lipid production; FFA and glucose oxidation in liver, muscle, and adipose tissue [103].
(vi) Exercise relies on the uptake of glucose by skeletal muscle, mediated by insulin that is produced in the pancreas. In some adults (e.g., those with Type 2 diabetes), skeletal muscle and liver tissues exhibit resistance to the action of insulin.
(vii) The total amount of energy available to a cell is limited. Exercise and high body temperature cause Na+-K+- pumps to operate at a high rate. Eventually, cells can become energy depleted, they swell due to reduced water transport (implying a reduced pump activity), and rigor mortis sets in, implying energy depletion [34, 76]

IM, intestinal microbiota; LPS, lipopolysaccharide; TNF-α, tumor necrosis factor alpha; IL-1β, interleukin-1β; IL-6, interleukin-6; IL-10, interleukin-10; ROS, reactive oxygen species; RNS, reactive nitrogen species; FFA, free fatty acid; a major component of the cell wall of Gram-negative bacteria.

5. Factors Which Increase Intestinal Permeability and Plasma LPS

Enterocytes are the predominant epithelial cells of the gut mucosal lining and form a physical barrier that limits passage of small molecules (molecular mass ≤ 500 Daltons) [52] (Figure 5). Enterocyte cell membranes are folded into finger-like microvilli which increase the surface area available for digestion and absorption of electrolytes, water, and other nutrients. Permeability can be increased via the following: (1) transcellular or paracellular active transport and endocytosis using channels (e.g., sodium-dependent glucose cotransporters (SGLTs), aquaporins), (2) changes in gap junctions, and (3) changes in adhesive complexes (junctions). Adhesive junctions include the following: (1) plasma membrane structures called tight junctions (TJ) comprised of multiple proteins (e.g., claudins, occludins, junctional adhesion molecules (JAMs)); zonula occludens (ZO proteins, actin); (2) multiprotein subjacent adherens junctions (AJ) including cadherin and catenin proteins; and (3) desmosomes.

Multiple risk factors for exertional heatstroke, including hyperthermia, sleep deprivation, dehydration, and aging, have been shown to directly affect the integrity of the intestinal barrier and thus intestinal permeability (Figure 5). Mechanisms by which transcellular and paracellular transport are affected to impact gut permeability include direct damage to tissue [31], sympathetic nervous system signaling [53], hypothalamic-pituitary axis activity [54, 55], phosphorylation [56], gene/protein expression [57], and inflammation-induced damage and signaling. It is intriguing to consider the multiple independent and perhaps cumulative effects of different stressors associated with EHS on intestinal permeability and downstream proinflammatory signaling.

5.1. Hyperthermia

Severe hyperthermia can disrupt the membrane structure of enterocytes (Figure 3), allowing endotoxin (i.e., LPS) to pass into the circulation, stimulating a systemic immune response characterized by proinflammatory cytokine release [58]. This response likely involves tight junctions, which exhibit increased leakiness to bacterial LPS (molecular mass 10–20,000 Daltons) after exposure to temperatures as low as 38.3°C, with larger molecules penetrating at temperatures higher than 41.5°C [59, 60]. The release of LPS from Gram-negative bacteria embedded in the mucosal lining, and its appearance in blood, is a potent agonist for the release of cytokines (e.g., interleukin-6, IL-6; tumor necrosis factor α, TNF-α), which exacerbate systemic inflammation in cases of severe heatstroke [42]. Case reports of EHS (i.e., considered to be a medical emergency) have involved the proinflammatory cytokines IL-6, TNF-α, and IL-1, as well as the anti-inflammatory cytokines IL-1RA, IL-10, and soluble TNF receptors [61].

Gaithram and colleagues [62] studied the role of LPS in EHS pathophysiology by passively heating 11 anesthetized monkeys to a rectal temperature of 43.5°C, then allowing them to cool in a 25°C environment; five received a prophylactic intravenous (i.v.) dose of hyperimmune plasma (i.e., containing antibodies to counteract LPS), and six control animals received an equivalent dose of nonimmune plasma. The former group experienced little or no increase of plasma LPS and 100% survival; 83% of the control group died, with elevated plasma LPS concentrations. This research team [63] also investigated the prophylactic administration of a nonabsorbable antibiotic via nasogastric tube (kanamycin, twice daily for 5 d), prior to passive heating (44.5°C rectal temperature). No increase of plasma LPS was observed in the four antibiotic-treated animals. In control animals, receiving no antibiotic, plasma LPS increased from 0.04 (37.5°C) to 0.06 (39.5°C) and 0.31 ng·ml−1 (44.5°C). These data suggested that the increased plasma LPS during heat stress originated mainly from the gut and supported research involving anesthetized dogs. Bynum et al. [64] reduced the intestinal stool and bacterial contents of dogs by administering antibiotics, cathartics, and enemas, before heating to a rectal temperature of 43.5°C. Following the reduction of gut flora, the incidence of 18 h survival rose from 20.0% to 70.6%. Antibiotics administered after heatstroke resulted in similar survival rates in experimental and control groups. Subsequently, Bouchama and colleagues [42] were able to describe, in baboons, differences between mild-to-moderate EHS and more severe cases. Nonsurvivors displayed significantly greater inflammatory activity and tissue injury than survivors. The animals with severe heatstroke exhibited a marked increase in plasma IL-6 levels which was strikingly similar to humans with near-fatal heatstroke, in whom the highest plasma IL-6 levels correlate with poor outcome [44]. Studying cytokine responses, Tracey et al. [65] passively immunized anesthetized baboons with TNF-α antibody fragments and then administered an i.v. LD100 dose of live Escherichia coli at two subsequent time points. Administration of antibodies 2 h before bacterial infusion provided complete protection against shock, vital organ dysfunction, persistent stress hormone release, and death. However, when antibodies were administered only 1 h before the bacterial challenge, critical organ failure occurred with no shock. Control, nonimmunized animals experienced hypotension followed by lethal renal and pulmonary failure. These experiments indicated that TNF-α mediated fatal bacterial endotoxic shock.

Based on the animal studies described above, increased plasma LPS is suspected to be an important etiological factor in the circulatory shock that accompanies advanced EHS in humans [31, 43, 66]. For example, elevated plasma LPS concentration reduces stroke volume, heart rate, and cardiac output by 30–50% in mice [67]. Although few studies have cultured bacteria from heat stroke patients, increased plasma LPS has been observed in (a) an EHS patient who presented with body temperature > 43°C and severe liver necrosis associated with Gram-negative sepsis [68] and (b) nonexertional heatstroke patients with core temperatures of ~42°C [69]. Under normal circumstances, endotoxin that leaks through the intestinal wall into the circulation is rapidly detoxified and inactivated in the liver [33]. However, under severe heat stress, the reduction in hepatic portal vein blood flow combined with thermally altered hepatocyte function severely reduces the capacity to detoxify a surge of endotoxin [48, 70]. The resulting increase of circulating LPS levels may result in fever, shivering, dizziness, nausea, vomiting, and diarrhea [71]. Table 6 presents the signs, symptoms, and laboratory variables which may be observed in cases of EHS; this table also illustrates multiple-organ dysfunction or failure. The majority of the factors in Table 6 also may be observed in patients who experience sepsis [43], a life-threatening condition that arises when the body’s responses to an infection injure its own tissues and organs [47]. Sepsis and septic shock are described in greater detail below, in the section titled Sleep Deprivation.

Signs and symptomsLaboratory/autopsy findings

(i)  Internal body temperature > 40°C 
(ii) Hyperventilation  
(iii) Headache 
(iv) Central nervous system involvement (loss of mental acuity, fatigue, weakness, confusion, dizziness, delirium, loss of coordination) 
(v) Hypotension 
(vi) Tachycardia 
(vii) Circulatory shock 
(viii) Liver failure 
(ix) Kidney failure 
(x) Nausea, vomiting 
(xi) Diarrhea
(i)  Intestinal ischemia 
(ii) Metabolic acidosis with respiratory alkalosis 
(iii) Elevated plasma lactate 
(iv) Elevated plasma LPS 
(v) Elevated plasma cytokines 
(vi) Elevated hematocrit 
(vii) Elevated liver enzymes (ALT, AST) in plasma 
(viii) Disseminated intravascular coagulation 
(ix) Leukocytosis 
(x) Neutropenia 
(xi) Tissue hemorrhage with necrosis 
(xii) Intestinal lesions

Sources. [43, 44, 119, 120].
5.2. Intense or Prolonged Exercise

Planned moderate-intensity exercise programs across several weeks represent a cornerstone in the primary prevention of chronic diseases [26] but stand in stark contrast to the acute physiological responses which occur during high-intensity exercise. For example, it is widely recognized that high-intensity exercise in a mild environment causes intramuscular pH to fall from 6.9 at rest to 6.4, and plasma pH to decrease similarly, after both intermittent and continuous maximal exercise [72]. But, to our knowledge, only one study has reported the pH of intestinal mucosa following maximal exercise in a mild environment [73]. The experimental protocol caused intramucosal pH to fall from 7.3 to 6.8, at the end of 30 minutes of maximal rowing ergometry. The authors attributed this acidotic state to decreased blood flow and intestinal hypoxia; other authorities have theoretically implicated [32, 34, 74] and empirically measured [75] energy (i.e., ATP) depletion in this process (a complete description of a theoretical energy depletion model involving EHS appears in [76]). Subsequently, Menconi and colleagues [77] reported that acidosis induced hyperpermeability in laboratory-cultured epithelial cells; a medium maintained at pH 5.4 increased both transcellular and paracellular movements of macromolecules. Thus, both high-intensity exercise and severe EHS induce lactacidemia and metabolic acidosis [43, 51]. Indeed, the plasma lactic acid concentrations of EHS patients reflect whole-body metabolic acidosis [78] and are significantly correlated with neurologic morbidity and mortality [79, 80]. Although it is unlikely that either of these two studies [72, 73] induced a markedly elevated body temperature, severe hyperthermia of internal organs is a primary, noxious etiological factor that reduces splanchnic blood flow [81]; increases intestinal permeability [31]; injures intestinal epithelial cells [34]; and stimulates hypercoagulability. Thus, maximal exercise and a rectal temperature > 41°C induce similar detrimental effects (i.e., resulting in endotoxemia) which likely are additive, when they occur simultaneously, as in EHS [82]. Experiments involving nonhuman primates suggest that LPS becomes increasingly important as a pathological agent as internal body temperature approaches 43.5°C [43]; above this temperature, direct thermal damage to enterocytes (Figure 3) and brain tissue is probably a more significant noxious stimulus [62]. Further it is possible, but undocumented, that cells of the intestinal epithelium generate lactic acid locally, via anaerobic metabolism, when splanchnic blood flow is low and splanchnic tissue is hypoxic [75, 77]. This is hypothetically significant because lactic acid penetrates the cytoplasmic membrane of Gram-negative bacteria and liberates LPS [83], more effectively than hydrochloric acid and EDTA—a preservative that prevents bacterial food spoilage.

Prolonged exercise also may cause plasma LPS to increase independently, or in combination with hyperthermia. For example, after a long distance triathlon (3.8 km swimming, 185 km cycling, and 42.2 km running) involving high altitude (3,200 m) and a maximal air temperature of 32.1°C, mild endotoxemia (68% of athletes) was observed [84]. Similarly, following a marathon footrace, eight out of 18 runners exhibited very mild endotoxemia (5 to 14 pg·ml−1), whereas one athlete had a high LPS level of 72 pg·ml−1 [85]. In mild ambient conditions (20–23°C), increased plasma LPS was observed in 81% of ultraendurance athletes who had completed an 89.4 km footrace [86] and in healthy runners following 1 h of strenuous treadmill exercise (80% of maximal aerobic power; final rectal temperature, 39.6°C) but not at two slower running speeds with lower rectal temperatures [87]. This suggests that the degree of LPS translocation into blood is proportional to the duration and intensity of exercise, during training [88] and competition [17]. The mechanisms of this increased gastrointestinal permeability theoretically involve reduced splanchnic blood flow which occurs during exercise [89, 90], the resultant hypoxic or acidic intestinal tissue, and/or reduced convective heat loss via blood, from central organs to the skin [31]. Intestinal ischemia has been shown to occur within 10–20 min of high-intensity exercise [91].

An interesting theory has emerged regarding the effects of repeated exercise-heat stress [92]. This paradigm involves the routine, repeated stimulation of host immune defenses during exercise-heat stress, via translocation of small amounts of LPS into the circulation of healthy individuals [93]. This theory applies to the chronic state known as “heat hardening” (i.e., the improved heat tolerance exhibited by long-term residents of hot climates) and to the superior but transient heat tolerance of highly trained individuals, gained by their daily exercise in the heat [94]. As noted in the previous paragraph, evidence shows that endurance athletes have elevated LPS antibody (anti-LPS IgG) concentrations at rest [84, 85, 88]. This suggests that individuals participating in regular strenuous physical activity or endurance training may develop an improved endotoxin tolerance [95] due to small, repeated exposures to LPS [94, 96, 97], in a form of self-immunization [88].

Another intriguing theory regarding the IM recently resulted from laboratory experiments which evaluated the endurance exercise performance of mice. Hsu and colleagues [98] examined whether gut bacteria would alter antioxidant enzyme levels and the exercise performance of 12-week-old male mice. Three varieties of animals were examined: mice containing no microorganisms, including the intestine (GF, ); those that were free of a specific pathogen by routine testing (SPF, ); and germ-free mice intentionally inoculated with Bacteroides fragilis bacteria (BF, ). Bacteroides fragilis are a Gram-negative anaerobic bacteria (Table 2) which provides beneficial effects to humans and animals. The absence of bacteria (GF group) decreased exercise performance time, but inoculation of germ-free mice with Bacteroides fragilis prevented the decline of endurance exercise time. In stating their unique findings, the authors noted that different microbial status altered exercise performance, possibly by altering innate antioxidant systems, as evidenced by lower levels of glutathione peroxidase and catalase in the serum and liver tissue of GF mice. Both of these enzymes normally defend against oxidative damage but become weaker during chronic fatigue and intense exercise [99]. Theoretically, improved activities of these enzymes (i.e., due to a consistent, progressive exercise training program) may counteract fatigue [100]. To our knowledge, this is the first evidence that the IM may influence endurance exercise performance directly. We find these results to be meaningful, considering that the IM theoretically may influence exercise performance in other ways, including carbohydrate and lipid absorption by enterocytes, energy metabolism, insulin sensitivity, free fatty acid oxidation, and electrolyte-water absorption [101103]. Further research is required to confirm these findings.

5.3. Exercise-Heat Acclimatization

During 10–14 days of exercise or labor in a hot environment, adaptations occur which improve exercise-heat tolerance, reduce physiological strain, and reduce the risk of EHS. Involving critical organ systems, these adaptations include expanded plasma volume and total body water, increased sweat rate, reduced heart rate, deep body temperature, sodium concentration in sweat and urine, and perceived exertion during exercise [104]. This process is named heat acclimatization in a natural environment and heat acclimation when exercise-heat exposure occurs in a controlled environmental chamber. Two studies are relevant to the influence of exercise training and heat acclimation on increased intestinal permeability. First, a research team led by Amorim et al. [105] supervised a 10 d heat acclimation protocol (42°C ambient temperature; walking or running for 100 min·d−1; 9 healthy adults). They assayed the plasma proinflammatory and anti-inflammatory cytokines which LPS stimulates (TNF-α, IL-1β, IL-6, and IL-10), heat shock protein 72 (Hsp72), and the enzyme lactate dehydrogenase as a marker of cell damage, before and after the 10 d intervention. This heat acclimation protocol did not alter the release of cytokines, nor did it change the degree of cellular damage. The level of Hsp72 increased across 10 d, in contrast with a study conducted in our laboratory, in which heat shock protein 70 was unaffected by 11 d of similar exercise-heat acclimation [106]. The authors [105] concluded that a heat acclimation program, which limits internal body temperature to <39°C, may not provide cellular tolerance to the stressors encountered during EHS. Second, Lim and colleagues [96] observed 18 trained distance runners during 14 d of endurance exercise in a mild environment. Before (T1) and after (T2) the training intervention, these men undertook a heat stress test (70% of their maximal aerobic power until rectal temperature reached 39.5°C) in a hot 35°C environment. Plasma LPS levels, and the cytokines IL-6 and TNF-α, were measured. The heat stress test induced mild endotoxemia during T1 and T2 but was well tolerated. The 14-day training program reduced plasma LPS concentrations, before exercise and at 1.5 hours after exercise. The authors concluded that these adaptations were not likely due to improved aerobic fitness (i.e., because the runners began this study in a highly trained state) or heat acclimation (i.e., because the only heat exposures were the exercise-heat stress tests). Rather, the authors proposed that frequent exposure to sublethal doses of LPS (i.e., as occurred between T1 and T2, during daily workouts in a mild environment) may inhibit LPS translocation and enhance LPS clearance by the liver [96]. Given the small number of publications regarding intestinal permeability during planned exercise-heat acclimatization, additional research is required.

5.4. Sleep Deprivation

Strenuous exercise can increase the plasma cytokine concentrations of IL-1β, TNF-α, and IL-6 in physically trained adults [107, 108]; these increases may persist for hours to days. Interestingly, both IL-1β and TNF-α are involved in the regulation of sleep; they are somnogenic, in addition to their role in inflammation [43]. Other cytokines also may influence sleep: IL-1 is produced as a result of sleep deprivation [109], and a stress-induced plasma IL-10 increase may alter sleep pattern and times [110]. These findings support earlier research studies that identified strong associative relationships between changes in sleep duration and immune function [111113]. Further, sleep loss was the most common (i.e., out of 16 total reported) predisposing factor or personal warning signal for EHS, experienced by 70% of former EHS patients. Thus, even though sleep deprivation is considered to be a risk factor for EHS, up to 64 h of sustained wakefulness in young, healthy individuals produced only minor, nonspecific clinical signs [114]; similarly, 9 days of voluntary sleep deprivation (i.e., with no inner organ hyperthermia) ended in collapse and hospitalization due to unspecified causes [115]. Thus, specific health impairments have not been definitively linked to sleep deprivation, the mechanism(s) are unknown, and no descriptive clinical signs have been identified for human sleep deprivation [116].

Observations of sleep-deprived animals suggest that host immune defense failure is central to the adverse effects of sleep deprivation, appearing as bloodstream infection. Specifically, bacterial and LPS translocation, and their pathogenic sequelae, provide possible mechanisms by which sleep deprivation appears to adversely affect health [116]. In severely sleep-deprived rats, for example, the proximal cause of death was infection by anaerobic bacteria from the IM, such as Pseudomonas aeruginosa, Klebsiella pneumoniae, Staphylococcus aureus, Streptococcus agalactiae, and Corynebacterium jejeikum [117]. These microorganisms do not cause primary bacteremia or threaten life unless the host is immunocompromised, but their presence in blood is highly lethal in humans [116]. Without the experimental administration of any agent except sleep loss, prolonged wakefulness produced a life-threatening hypermetabolic and systemic inflammatory state in rats that was not accompanied by the usual diagnostic symptoms of fever and large tissue inflammation. Because of the nonlocalized and toxic-like nature of sleep deprivation (i.e., the rapid reversibility of debilitation via sleep), without evidence of permanent damage, the most plausible cause of death [117, 118] from sustained sleep deprivation was septicemia (i.e., bloodborne bacterial infection).

More than twenty years after these animal experiments (i.e., despite numerous publications regarding the pathobiology, biochemistry, immunology, management, and epidemiology of sepsis), a 19-member task force [47] acknowledged that sepsis, septic shock, and systemic inflammatory response syndrome (SIRS) are difficult to diagnose. This task force also concluded that (a) sepsis is not a specific illness but a syndrome that encompasses an uncertain pathobiology and is without a validated standard diagnostic test; (b) septic shock is a subset of sepsis in which the underlying circulatory and cellular/metabolic abnormalities increase mortality substantially; and (c) the term severe sepsis is redundant. Although SIRS has been implicated in the pathophysiology of EHS [82], and although the clinical and laboratory results observed in cases of EHS (Table 6) are similar to sepsis and septic shock [43, 44, 119, 120], the relationship remains theoretical. Importantly, both EHS and septic shock exhibit systemic inflammation leading to a syndrome of diffuse, nonlocalized multiorgan dysfunction or failure (Table 6; [44, 47]). Indeed, EHS has been named “heat sepsis” because of the essential etiological role that LPS plays [121].

5.5. Dehydration

Dehydration may contribute to reduced intestinal blood flow, causing tissue hypoxia and heightened intestinal permeability [122]. Also, human prehydration with intravenous fluid (1.5 L of 2.5% glucose/0.45% NaCl), 1 h prior to an injection of Escherichia coli purified LPS endotoxin, may shift the resulting cytokine balance towards a more anti-inflammatory pattern, with a reduction of symptoms [123] and an outcome that is similar to the successful treatment of sepsis (i.e., life-threatening organ dysfunction caused by a dysregulated host response to infection [47] via i.v. fluid [124, 125]). To evaluate the effects of dehydration on gastrointestinal permeability, Lambert and colleagues [122] conducted a laboratory study in which twenty trained endurance athletes (11 men, 9 women) ran three times, in a 24°C mild environment, for 60 min at 70% of maximal aerobic power. During three double-blinded, randomized experiments, participants consumed either a 4% glucose solution (GLU), a placebo fluid (PLA), or no fluid (NF). Running increased GI permeability compared to rest, with the greatest permeability occurring during the NF trial. GI permeability did not significantly increase above resting levels when fluid was ingested at a rate sufficient to offset sweat losses (GLU and PLA). Although the increase in GI permeability in the NF trial did not result in greater gastrointestinal symptoms or cause any other noticeable problems, the authors [122] commented that barrier dysfunction likely would have worsened, with more prolonged or intense exercise.

5.6. Diet

Commensal gut microbes digest food components and release a variety of metabolites that are involved in the mutualistic balance achieved between microbiota and the host [126] (i.e., both partners benefit). The IM and its collective genomes (i.e., the microbiome) accomplish important metabolic functions and provide us with the ability to harvest otherwise inaccessible nutrients and energy. For example, Bacteroides thetaiotaomicron is prominent in the distal intestine of adult humans. This successful commensal anaerobe has an exceptional capacity for digesting otherwise indigestible dietary polysaccharides. Its glycobiome contains one of the largest sequenced gene ensembles that metabolizes carbohydrates (i.e., 226 predicted glycoside hydrolases and 15 polysaccharide lyases) [127]. By contrast, the human genome contains only 98 known or presumed glycoside hydrolases and is deficient in the enzyme activities required for degradation of xylan-, pectin-, and arabinose-containing polysaccharides that are common components of dietary fiber [128]. Numerous other anaerobic bacteria are capable of digesting plant materials, including nondigestible carbohydrates, nonstarch polysaccharides, resistant starch, and oligosaccharides [129] which humans cannot process. The metabolic intermediates and end-products which result from bacterial fermentation of these materials (Table 2) include short-chain fatty acids (SCFA; butyrate, propionate, acetate, and succinate), modified bile acids, and vitamins [130132]. The SCFA, especially butyrate and propionate, regulate host glucose metabolism and immunity favorably, resulting in reduced proinflammatory cytokine production [130, 133]; are important in water and electrolyte absorption in the colon; modulate colon and liver blood flow; encourage colon mucosal integrity [102]; reduce intestinal permeability; and modulate chronically elevated plasma LPS [134].

Tables 35 describe a few of the many interactions between diet (i.e., nutrients, biochemical substrates) and physiological functions (e.g., digestion) that are relevant to EHS. For example, during daily activities, diet modulates inflammation and immune function, pH of the mucosal lining surrounding intestinal epithelial cells, intestinal permeability, and glucose homeostasis, insulin secretion, and energy metabolism [103, 133, 135]. In our opinion, these effects qualify diet as a predisposing factor for EHS.

In recent years, research involving the interactions between diet, the IM, and immune functions have focused on obesity, insulin resistance, and the metabolic syndrome. A large body of research in mice indicates that the IM is involved in the development of these disorders and that chronic, low-grade inflammation is part of their etiologies. This condition has been named metabolic endotoxemia because elevated plasma LPS levels have been identified as the prime factor in the low-grade inflammation and insulin resistance which occurs in the liver, muscles, and adipose tissue [40]. Metabolic endotoxemia is an example of dysbiosis (i.e., a disruption of the normal, healthy balance between the gut microbiota and host) that reflects lifestyle decisions (e.g., diet, exercise) and host genomic interactions [17]. Conducting an exquisitely designed series of mice experiments, Cani and colleagues reported the following findings. First, altering the bacterial composition of the IM in two strains of mice (i.e., nutritionally and genetically obese) increased plasma LPS and low-grade inflammation, type 2 diabetes, and insulin resistance [136, 137]. Second, the relevance of LPS signaling to the development of diet-induced low-grade inflammation was verified in mice lacking the immune cell receptor for LPS (toll-like receptor-4, TLR-4). Third, they demonstrated that metabolic endotoxemia, produced by chronic subcutaneous infusion of LPS (i.e., mimicking metabolic endotoxemia), significantly induced insulin resistance and inflammation [40]. Fourth, researchers interfered with LPS signaling by administering subcutaneous LPS quenchers (i.e., antibiotic or endotoxin inhibitors) for 4 weeks in genetically obese mice; significant decreases of inflammation occurred, together with improved glucose tolerance and insulin resistance [136]. Other experiments, involving genetically altered strains of mice [138] and antibiotic treatment [139], similarly demonstrated the contribution of gut-derived LPS to metabolic endotoxemia. This inflammatory abnormality is only one of a large variety of human diseases that are classified as immune system disorders and which involve increased plasma LPS (Table 5).

The relationships between a high-fat diet, LPS, obesity, and Type 2 diabetes also have been investigated in human test subjects. For example, Erridge et al. [35] and Ghanim et al. [140] examined baseline endotoxin concentrations in healthy human subjects and found that a high-fat meal (versus no meal) or a high-fat, high-carbohydrate meal (versus a high-fiber and fruit meal) increased plasma LPS concentration. Dogan and colleagues [141] reported a similar effect after consuming a high fructose diet. A link between metabolic endotoxemia, high energy intake, and a high-fat diet also was observed in a cohort of 201 men [142] and in multiple independent studies [143145]. One of these [146] reported that LPS can increase adipose proinflammatory cytokine release (e.g., TNF-α and IL-6) and insulin resistance. Considered together, these mice and human investigations strongly suggest that the IM and diet contribute to LPS-related metabolic endotoxemia independently and concurrently [40].

Relevant to EHS, we propose that a state of chronic metabolic endotoxemia [17, 40, 136, 137], involving increased intestinal permeability, can be potentiated or multiplied by hyperthermia, high intensity/prolonged exercise, reduced blood flow to splanchnic organs, enterocyte hypoxia, and acidity, as described above. An animal model of heatstroke supports this proposition. Lin et al. [147] observed rats with a preexisting inflammatory state, induced by exogenous administration of i.v. LPS, at the point that rectal temperature reached 42.5°C. When compared to a saline control group, the LPS-treated rats exhibited greater inflammation (i.e., increased plasma IL-6, TNF-α, and IL-1β), hypercoagulation, and multiorgan dysfunction (i.e., increased plasma creatinine, blood urea nitrogen, alkaline phosphatase, aspartate aminotransferase, and alanine aminotransferase). The authors concluded that a preexisting inflammatory state can exacerbate the multiorgan injury during heat exposure.

5.7. Chronic Inflammation and Illness

LPS affects the brain and central nervous system in several ways. Fever, for example, is a regulated rise of body temperature, provoked by invading microorganisms and LPS. A widely accepted theory states that LPS stimulates bloodborne immune cells (i.e., monocytes and macrophages) to produce cytokines (e.g., IL-1β, IL-6, IL-8, TNF-α, and interferon-γ) which, in turn, mediate fever by stimulating prostaglandin E2 in the organum vasculosum laminae terminalis (OVLT) of the brain; OVLT nerve impulses then stimulate the hypothalamus, which regulates whole-body heat balance. An alternative theory suggests that LPS influences the OVLT-PAH area of the brain via peripheral vagal nerves which sense the presence of LPS in the liver [148]. Regardless of the pathway, much evidence indicates that immune system responses to LPS have acute central effects [149]. In cases of chronic inflammation, lymphocytes and macrophages predominate, and the cytokine IL-6 is critical to the control of local and system-wide inflammation [150] and the transition from acute to chronic inflammation. In chronic autoimmune diseases (i.e., rheumatoid arthritis, lupus, and psoriasis), plasma IL-6 is elevated and sustains inflammation via T-cells and B-cells [151].

Crohn’s disease (CD) and ulcerative colitis (UC) are the two primary chronic inflammatory bowel diseases (IBD). Several lines of research evidence suggest that the IM influences the pathogenesis of these diseases. Although most studies of IM influences have analyzed fecal contents, the work of Frank and colleagues [152] analyzed tissues obtained from CD patients, UC patients, and non-IBD control subjects during surgery at a variety of small intestinal sites; tissues included both pathologically normal and abnormal tissues. Their comprehensive rRNA sequence analysis of the IM indicated that a subset of CD and UC samples were characterized by depletion of commensal bacteria, notably members of the phyla Firmicutes and Bacteroidetes. Further, patients stratified on the basis of their IM (a) showed that CD represents a spectrum of disease states, and (b) suggested that treatment of some forms of IBD may be facilitated by rectifying microbiological imbalances [152]. Chronic, low-grade systemic inflammation induced by LPS has been associated with other diseases and lifestyle factors, including the following: insulin resistance, obesity, and diabetes [153], colorectal cancer [154], and alcoholism and liver cirrhosis [155, 156]. Regarding the latter conditions, (a) selective intestinal decontamination with antibiotics results in a decline of plasma LPS and attenuated liver damage in animal models of alcoholic liver disease [157] and (b) dysbiosis of the IM occurs in alcoholics, who have a lower abundance of butyrate-producing bacteria (i.e., generally believed to be anti-inflammatory) and a higher abundance of bacterial phyla believed to be proinflammatory [156, 158].

5.8. Acute Illness and Infection

Individuals with a preexisting barrier dysfunction, bacterial infection, or febrile illness may be at greater risk of developing EHS. When these conditions exist prior to exercise, internal body temperature may begin well above 37°C, and it may reach the 40°C clinical threshold of EHS sooner than in healthy individuals [3, 159]. Evidence for this statement exists in a published case report of a 21-year-old man who exhibited slight hyperthermia (39.1°C) during the third consecutive day of laboratory-controlled, light treadmill exercise (100 min, 40°C environment). His elevated rectal temperature, according to the authors, was associated with an acute local infection of a foot friction blister [160], diagnosed as cellulitis and treated with antibiotics. Because the incubation period for bacterial cellulitis extends across several days, this infection was subclinical (i.e., not recognized by the young man) before abnormal thermoregulation occurred.

Not surprisingly, a number of studies have implicated illness with fever as a predisposing factor to EHS [50]. One case report involved a 19-year-old man who experienced EHS twice during prolonged marches, separated by only one month [161]. His first EHS involved clinically overt gastroenteritis, which diminished his exercise-heat tolerance. The authors suggested that a subclinical infection may have predisposed the second event. Additionally, twelve years of epidemiological data, recorded in a military hospital, showed that more than 95% of EHS patients had mild fever, upper respiratory tract infection, or diarrhea prior to their event [162]. However, if a highly motivated young individual does not perceive overt EHS symptoms, or has mild symptoms of EHS, he/she may exercise to the point of collapse when under the discipline of sport competition, work, or military maneuvers. Under other circumstances, these same individuals typically would have remained at home when ill and would have rested when fatigued [51].

Healthy young individuals who experience EHS are generally unaware of the subtle signs or seriousness of their increasing hyperthermia during exercise (i.e., rectal temperature approaching 40°C), relative to the familiar signs of fatigue or exhaustion [74, 163]. Premonitory signs of illness, during the days prior to EHS, may be their only advanced warning. Such signs were reported by 10 infantry soldiers (mean ± SD; age,  y; body fat, %; maximal oxygen consumption,  ml·kg−1·min−1) who participated in prospective laboratory testing, days after an episode of EHS [164]. Six of these former patients recognized prodromal signs of impending illness (e.g., headache, dizziness, lack of coordination, and disorientation; Table 6) during the 5 d prior to EHS. Interestingly, 80% of these men experienced EHS (rectal temperature, °C) while running at a relatively slow pace (12.1–13.8 km·h−1), during morning (0630–1000 h) group physical training (distance,  km), when the environmental temperature was not harsh (dry bulb temperature, °C) but the relative humidity was high . This implicated a preexisting illness as a predisposing factor. Gastroenteritis (i.e., stomach or intestinal flu) is a prime example, involving symptoms such as watery diarrhea and vomiting (i.e., resulting in dehydration), abdominal pain, cramping, fever, nausea, and headache. Viral pathogens in the genera rotavirus and norovirus, as well as bacterial pathogens such as Escherichia coli and Salmonella enterica, are the most common cause of gastroenteritis.

Lin and colleagues [147] investigated the effects of a preexisting LPS-induced acute inflammatory state on organ function. They compared normothermic rats treated with normal saline (CON), normothermic rats treated with LPS (L), heat-stressed rats treated with normal saline (H), and heat-stressed rats treated with LPS (HL). The H and HL groups were exposed to a 43°C environment for 53 minutes. Measured variables included proinflammatory cytokines (IL-1α, IL-6, and TNF-α), biomarkers of organ dysfunction (liver ALT and AST, renal creatinine, and BUN), and blood coagulation factors (prothrombin time, D-dimer, and protein C). These measured variables increased progressively, as follows: CON > L > H > HL. This supported the concept that preexisting endotoxemia exacerbated overproduction of proinflammatory cytokines, hypercoagulation, and organ injury [147]. Similarly, Leon and Dineen [165] reported that injection of a virus (48 h and 72 h prior to heat exposure) exacerbated EHS severity and survival in mice during recovery, even after sickness behaviors had extinguished.

Considered together, the above observations suggest that the existence of endotoxemia or infection, before and during strenuous exercise-heat exposure, increases the risk of EHS [121]. These findings also suggest that optimizing the intestinal barrier and immune system defenses may reduce the risk of EHS morbidity and mortality. Indeed, one theory [66, 121] views the development of EHS along two paths: endotoxemia and heat toxicity. In the former, EHS is viewed as an illness which originates within the gut, when GI temperature is 42°C or less, as the rate of LPS translocation into blood overwhelms the rate of LPS clearance by Kupffer cells in the liver. The resulting endotoxemia leads to systemic hypotension, cardiovascular shock, and disseminated intravascular coagulation [4447], sometimes existing without hyperthermia. This interesting concept may explain why some cases of EHS occur in cool or mild environments [41, 161, 164, 166]. In the second theoretical pathway [66], severe hyperthermia above ~42°C causes damage to the cytoskeleton and other cellular structures and eventually leads to multiorgan necrosis and death [43, 74, 76]. The authors of this theory believe that the former path (i.e., endotoxemia) transitions to the latter (i.e., hyperthermia) but that no information exists regarding the mechanism of this transition [121]. This distinction may have greater academic than medical value because, in clinical practice, EHS therapy involves immediate aggressive whole-body cooling, transport to an emergency care facility, treatment of signs and symptoms, and monitoring of laboratory tests during recovery [2, 3, 167]. In severe EHS cases, both endotoxemia and hyperthermia act in concert to induce multiorgan dysfunction and damage.

5.9. Aging

Plasma levels of LPS are elevated in older adults [168, 169], and they may experience chronically increased inflammatory tone, apparent as increased concentrations of the inflammatory markers TNF-a, IL-6, IL-8, and C-reactive protein [16, 170]. Reduced microbial diversity and stability [16, 171], as well as changes in the predominant bacterial phyla, also may occur. Williamson et al. [172] reported that adults older than 74 years experienced a 10-fold increase of blood infections with Escherichia coli, Gram-negative bacteria, when compared to adults aged less than 50 years. Likewise, Klevens and colleagues [173] observed that older (versus younger) adults experienced an increased incidence of blood infections with Staphylococcus aureus, Gram-positive bacteria. This may occur because elderly subjects exhibit a prolonged inflammatory response (i.e., TNF-α, and IL-10), relative to younger participants, when hospitalized with a pneumococcal infection [174]. Only a small number of publications have focused on the influence of aging on intestinal permeability, and no research studies have evaluated age-related differences of inflammatory tone in EHS patients. However it is widely recognized that older adults experience EHS and nonexertional heatstroke more commonly than their younger counterparts, as reported in multiyear studies involving Japanese citizens [175], and Muslims participating in the desert pilgrimage to Mecca [176]. This latter study described 125 EHS cases, showing that incidence rose precipitously across the age groups 40–49, 50–59, and 60–69 years; 58% of these EHS patients were 60 years or older. This phenomenon may be related to decreased cardiovascular physical fitness and heat intolerance in the elderly, but that was not the case in a report involving South Africa laborers [177], where the age threshold for an increased incidence of EHS in deep mines was >40 years. Also, preexisting comorbidities (e.g., hypertension, diabetes) may affect thermoregulation, heat tolerance [178], and systemic inflammatory tone.

5.10. Nonsteroidal Anti-Inflammatory Drugs

Ironically, evidence suggests that it is unwise to use a nonsteroidal anti-inflammatory drug (NSAID) to reduce pain, fever, and inflammation, prophylactically or after exercise. Short-term and prolonged moderate-intensity or low-intensity aerobic exercise, when combined with aspirin or ibuprofen use, may increase gastrointestinal permeability and the risk of endotoxemia [46, 179181]. A controlled field study involving 29 ultramarathoners provided evidence of this effect [182]. Runners consumed 600 mg of ibuprofen on the day before, and 1200 mg on the day of, an arduous 160 km endurance event in a cool-to-moderate environment. When compared to 25 control runners (no NSAID intake), those who ingested ibuprofen experienced significantly higher LPS and proinflammatory cytokine (IL-6, IL-8, and IL-10) concentrations in plasma. Interestingly, no between-group differences were observed in race time, gastrointestinal discomfort, perceived muscle soreness, or muscle damage biomarkers in plasma. Human investigations, conducted at rest in mild environments, also have demonstrated that NSAID increase plasma cytokine concentrations. When given i.v. LPS (Escherichia coli endotoxin), participants developed fever (rise of 1.3°C) and illness symptoms including chills, myalgia, headache, and nausea at 1 h that were diminished by 5 h after injection. A 4- to 10-fold increase of TNF-α, and a 10-fold increase of IL-6, occurred 1.5–3 h after an 800 mg ibuprofen pretreatment and subsequent challenge with i.v. LPS; the control experiments involved i.v. normal saline prior to the LPS challenge [183, 184]. The peak levels of TNF-α (i.e., a primary mediator of septic shock and organ failure) were considerably higher than the levels commonly observed in patients with sepsis [184]. The mechanism is unknown, but two hypotheses are relevant to intestinal ultrastructure and function [185]. First, NSAID may reduce prostaglandin production in the intestinal mucosa, resulting in damage via oxygen free radical production and enterocyte microvascular vasoconstriction [186]. Second, NSAID may reduce cellular ATP production by inhibiting energy production at specific steps in the glycolytic and tricarboxylic acid cycle pathways [187]. Together, these actions may affect intestinal epithelial cells in a way that orchestrates failure of energy-dependent intracellular mechanisms, which regulate the integrity of tight junctions [188]. Also, it is likely that several other medications are absorbed by increasing intestinal permeability, via the action of tight junctions [189, 190]. These research findings are disturbing, considering the widespread use of NSAID by endurance athletes. During the 2004 New Zealand Ironman triathlon, for example, 30% of competitors consumed NSAID during the race [191], whereas, during the 2008 Brazil Ironman event, 43% of triathletes who were surveyed consumed NSAID one day before, 68% immediately before, and 89% during the race [192]. A study of runners at the 1996 Chicago marathon also reported that 75% of subjects ingested aspirin or ibuprofen before or during the race [193].

5.11. Prescription Medications and Drugs of Abuse

Pharmacologic agents have been recognized for more than 50 years as predisposing or causative factors for nonexertional heatstroke, exertional heatstroke, and drug-induced hyperthermic conditions [17, 51, 120, 194, 195]. The classes of these drugs include anticholinergics, antihistamines, monoamine oxidase inhibitors, amphetamines and their analogues, diuretics, antihypertensives, antipsychotics, and antidepressants [43, 51, 196, 197], plus inhalation anesthetics which affect individuals who have a genetic susceptibility for malignant hyperthermia [198, 199]. Because each drug has unique pharmacologic effect(s) on cells, tissues, and organs [200] and because human thermoregulation is complex, it is impossible to reduce these effects to a single mechanism. However, authors have attributed fatal hyperthermia to numerous effects, including increased metabolic heat production; diminished sweat production or skin blood flow; interference with hypothalamic temperature regulation or cardiac output; and fluid-electrolyte imbalances [44, 51, 74, 132, 165, 194, 196, 201, 202].

Overdoses of psychostimulant drugs such as cocaine, amphetamine, methamphetamine, and ecstasy (i.e., 3,4-methylenedioxymethamphetamine, MDMA) are of particular interest because hyperthermia is common in severe or lethal poisonings and may be the primary mode of death [196, 203, 204]. Even though their central and peripheral effects are unique, these drugs share a final common pathway with EHS: stimulation of the sympathetic nervous system and increased heat production [195, 204]. In cases of EHS [4447] and in cases of drug overdose, with or without hyperthermia [205207], disseminated intravascular coagulation, rhabdomyolysis, and liver injury occur. Indeed, severe EHS and cocaine intoxication share many clinical signs and symptoms [4]: combative behavior, coma, nonpyrogenic hyperthermia, acute renal failure, oliguria, hyperuricemia, rhabdomyolysis, hypotension, seizure, myoglobinuria, hypocalcemia, disseminated intravascular coagulation, multiorgan hemorrhage, and hepatic damage (i.e., elevated plasma ALT, AST, and bilirubin). These commonalities suggest similar etiologies for EHS and cocaine intoxication, and that the primary suspected noxious insults are hyperthermia and oxidative damage in tissues. The mechanisms responsible for the oxidative damage induced by hyperthermia are not fully understood, but it is known that they include formation of reactive oxygen species (e.g., superoxide and hydroxyl radicals) in liver tissues and that the resultant oxidative stress mediates heat-induced cellular damage [208, 209].

Because oxidative stress has been implicated in neurodegenerative diseases, aging, cancer, and vascular diseases, elimination of unwanted reactive oxygen species is very important [210]. In controlled laboratory investigations of organ damage via overdoses of acetaminophen [211, 212], cocaine [213], MDMA [214], amphetamine [215], and morphine [216, 217], oxygen free radicals played an important role in hepatotoxicity [218]. Two additional studies support this concept. First, vitamin E (i.e., an inherent antioxidant defense against toxic free radical species) deficiency increased susceptibility to MDMA-induced neurotoxicity and hepatic necrosis [219]. Second, when mice were treated with morphine plus two exogenous antioxidants (i.e., glutathione and ascorbic acid), the damaging effects of morphine on liver cells was completely abolished [217]. However, it is difficult to identify the exact pathways by which drugs induce acute and chronic liver damage, because various pathways of cell death are triggered, with significant crosstalk and overlap. These involve disruption of hepatocyte ultrastructures (e.g., membrane, nucleus, and cytoplasm) and processes (e.g., gene translation, RNA cleavage) [220].

Both LPS and the proinflammatory cytokines (i.e., TNF-α, IL-1) mediate hepatotoxicity in response to a variety of chemicals (e.g., carbon tetrachloride, acetaminophen, α-naphthylisothiocyanate, alcohol, and galactosamine) [221224]. In one relevant, controlled laboratory investigation, Meng et al. [225] observed two groups of mice: those treated with morphine (pellet implantation, 24 h) and a control group (placebo pellet, 24 h). Plasma levels of morphine were in the range experienced by opioid abusers and patients taking opioids for moderate-to-severe pain. Employing a variety of techniques, researchers determined that morphine disrupted the tight junctions which connect small intestine epithelial cells, increased gut permeability, allowed bacterial translocation (i.e., plate incubation) to the liver and lymph nodes surrounding the intestine, and fostered enterocyte tissue inflammation (i.e., microscopic examination of histological sections). Other rodent studies have determined that (a) chronic morphine use accelerates the progression of LPS-induced sepsis to septic shock [226]; (b) both chronic morphine and morphine withdrawal lower host immune defense against IM bacteria (reviewed in [225]); and (c) the opioid antagonist naltrexone (i.e., a prescription drug used in the management of alcohol and opioid dependence) blocks acute endotoxic shock in mice by inhibiting TNF-α production [227]. These studies have implications for individuals and governmental health care, because morphine and other opioid drugs are the most widely prescribed and abused pain medications in the United States.

6. Advanced Planning and Education Reduce EHS Morbidity and Mortality

In most cases of EHS, exercise induces hyperthermia due to a situation (e.g., sport competition, work site, or military activities) that pushes a healthy, young athlete, laborer, or soldier to the point of collapse and medical emergency [51]. Knowing this, attempts to reduce EHS morbidity and mortality begin with awareness and prevention. First, laborers and athletes who perform strenuous work or exercise in warm or hot environments (a) must understand the nature and predisposing factors of EHS (Table 1); (b) recognize the early warning signs of EHS (i.e., dizziness, headache, loss of coordination, great fatigue, and nausea; Table 6); (c) limit exercise/work intensity and duration to their present level of physical fitness and heat acclimatization; and (d) consume adequate fluids. Second, supervisors (i.e., race organizers, medical directors, foremen, and military officers) must modify exercise-rest or work-rest cycles in real time by monitoring environmental conditions [2]; recognize that central nervous system involvement (e.g., loss of mental acuity, confusion, and aberrant behavior) is a hallmark sign of EHS, a medical emergency [3]; and prepare cold water, ice, and large immersion tubs as emergency treatment for EHS [167, 228]. Although EHS cannot be predicted, hyperthermic death and circulatory shock can be avoided in virtually all cases, with early recognition and rapid immersion in cold or ice water [2, 3, 229, 230]. In addition to conductive cooling, water immersion supports the central circulation via external hydrostatic pressure and skin vasoconstriction.

7. Do Foods or Nutritional Supplements Augment the Intestinal Barrier and Immune Function?

Preexisting baseline endotoxemia or viral infections are believed to exacerbate hypercoagulation, the production of proinflammatory cytokines, and organ injury in cases of EHS [50, 147, 165]. Recognizing plasma LPS level as a measurable and critical factor in the development of EHS, the preceding text describes several intrinsic characteristics and behaviors that increase intestinal permeability, thereby increasing the risk of severe EHS. The following paragraphs consider foods and nutritional supplements that (a) have anti-inflammatory or antioxidant effects and (b) facilitate effective immune responses. The effects are accomplished via influences on IM homeostasis, intestinal permeability, liver function, or immune defenses.

7.1. Probiotic Supplements

The number of bacteria administered with a daily probiotic dose, in capsule or tablet form, is approximately 109 or 1010 cells. In comparison, the complex human IM bionetwork is 1,000–10,000 times larger (1013 organisms). Thus, in terms of sheer numbers, it is somewhat surprising that probiotics remain in the gut or exert measurable effects on physiology, metabolism, and immunity [231, 232]. Also, in terms of intestinal secretions, probiotic bacteria also must be resistant to gastric acidity and bile salts (Table 3). Research evidence suggests that this is possible, in that Bifidobacterium longum can persist in the gut of 30% of individuals for at least 6 months after oral consumption, without causing gastrointestinal symptoms or altering the species composition of the resident microbiota [233]; this should be interpreted in view of the fact that longevity may not be characteristic of other species [234, 235].

The functional targets of probiotics include electrolytes and water absorption, lactose digestion/absorption, mucosal integrity, and epithelial proliferation and repair [236]. To our knowledge, there is little evidence to suggest that people with a normal IM ecosystem can benefit from probiotic consumption [231]. However, substantial evidence suggests that oral probiotic use imparts positive effects on a variety of human illnesses and chronic diseases, including gastroenteritis, lactose intolerance [237], infectious diarrhea in children [238], antibiotic-associated diarrhea, Helicobacter pylori, Clostridium difficile disease [239], and incidence and mortality due to necrotizing enterocolitis in premature infants [240]). Probiotics may or may not alleviate some of the symptoms of irritable bowel syndrome, a condition for which the current support is weak [239, 241]. Negative effects of administering probiotics directly into the intestine [242] have been reported among patients hospitalized with severe pancreatitis (probiotics group, ; placebo group, ). This randomized, double-blinded protocol did not reduce the risk of infectious complications and was associated with an increased risk of mortality (probiotics group, 16%; placebo group, 6%; relative risk, 2.53). The authors speculated as to the cause of these deaths in critically ill patients, mentioning the administration of 10 billion probiotic bacteria per day, plus enteral nutrition, in the same region of the intestine. This intervention might have aggravated local inflammation of the intestinal mucosa, reduced capillary blood flow to enterocytes, and induced ischemia [242].

As noted above, EHS involves disrupted intestinal barrier integrity due to hyperthermia (Figure 3), decreased splanchnic blood flow, and enterocyte hypoxia. Relevant to EHS and metabolic endotoxemia, several controlled investigations have evaluated the influence of probiotic consumption on intestinal barrier integrity, with positive outcomes. These studies indicate that probiotics may initiate repair of damaged epithelial cells by redistributing tight junction proteins and restoring the mucosal lining which surrounds enterocytes [234, 243246]. It also is well established that probiotic bacteria can suppress intestinal inflammation [234] by downregulating LPS receptors on epithelial membranes, secreting metabolites (Table 2), and/or inhibiting cell signaling in humans and in mice [247, 248]. Lamprecht and colleagues [249] reported similar findings during a randomized, double-blinded, placebo-controlled study that compared a probiotic containing six bacterial strains () to a placebo (), during a 14-week treatment phase. They reported that probiotic supplementation improved intestinal barrier function and low-grade inflammation in men under sustained exercise stress (80–90 minutes of strenuous exercise). Several other single-strain probiotics are reported to provide beneficial effects on intestinal barrier function, by modifying expression and localization of tight junction proteins in the space between enterocytes [249]. Unfortunately, hundreds of bacterial species exist in the human IM ([8]; Table 2, Figure 1), probiotic effects are likely to be strain specific [234, 235, 250], and targeted prophylactic benefits are difficult to validate scientifically in controlled, randomized trials.

7.2. Anti-Inflammatory and Antioxidant Foods

Diet, by providing the substrates for bacterial metabolism, can modulate inflammation and immune function, pH of the mucosal lining surrounding intestinal epithelial cells, intestinal permeability, gut hormone release, glucose homeostasis, insulin secretion, and energy metabolism [103, 133, 135, 251] and regulate epithelial permeability by modifying expression and localization of tight junction proteins in the paracellular space [252]. Low-grade plasma LPS increases adipose proinflammatory cytokine release (e.g., TNF-α and IL-6) and may contribute to insulin resistance [146]. Also, the composition and biological functions of the IM (Figure 2) are different in humans who consume vegan, vegetarian, and omnivorous diets, as well as those high in red meat [253, 254]. Thus, we propose that habitual dietary choices may predispose individuals to EHS because of a preexisting increase of plasma LPS and low-grade inflammation, and human food consumption patterns are reflected in both the IM and its collective genome [12, 255, 256]. Our proposal is supported by a 2013 porcine investigation which evaluated the influence of different dietary oils on intestinal LPS transport and serum endotoxemia, following a single meal [257]. Four groups of animals consumed one meal of 500 g ground corn-soybean meal dough; this was mixed with either 50 ml water (control), 50 ml fish oil, 50 ml vegetable oil, or 50 ml coconut oil (one per group). Relative to the control condition, postprandial serum LPS concentration (and a measure of intestinal permeability to LPS) increased after a meal rich in saturated fatty acids (coconut oil) but decreased after a meal containing higher omega-3 fatty acids (e.g., cod liver and fish oils).

Changing the composition of one’s diet rapidly shifts the microbial ecosystem [253, 258260]. This effect was observed within 24 hours, during a controlled-feeding study of 10 adults who initiated a high-fat/low-fiber or low-fat/high-fiber diet [256]. Similarly, a shift of the IM was observed within 24 h, during both phases of a study involving a plant-based diet (i.e., rich in grains, legumes, fruits, and vegetables) and an animal-based diet (i.e., predominantly meats, eggs, and cheeses). Bacteroides was highly associated with animal protein, a variety of amino acids, and saturated fats; Prevotella, in contrast, was associated with high intakes of carbohydrates and simple sugars [253]; both are Gram-negative anaerobic bacteria. These effects are modest and reversible and vary among individuals [14, 129, 253, 254].

Virtually all bacteria in the colon digest plant materials via fermentation [129]. The resulting metabolic products (Table 2) include short-chain fatty acids (SCFA) [130, 131, 133]. The SCFA (e.g., butyrate, acetate, and propionate) are generated by Gram-negative and Gram-positive bacteria [131, 261], mostly by fermentation of dietary carbohydrates that humans cannot digest (i.e., nonstarch polysaccharides, resistant starch, and dietary fiber) [129]. Butyrate is an important energy source for intestinal columnar epithelial cells (i.e., preventing mucosal degradation) [262] and influences tight junction protein expression [101]. Relevant to EHS, SCFA in general influence colon and liver blood flow, encourage colon mucosal integrity [102], and modulate both plasma LPS [134] and cytokine responses [130, 133]. Table 7 presents foods that have moderate-to-high anti-inflammatory and antioxidant qualities. A diet that is rich in vegetables, fruit, nuts, and fish theoretically encourages colonic health by minimizing inflammation and counteracting oxygen free radicals [263268]. In support of this concept, Ghanim and colleagues [140] reported that a single high-fat, high-carbohydrate meal (i.e., 41% carbohydrate, 17% protein, and 42% fat) increased plasma LPS (+47%) and elevated production of reactive oxygen species (+65 to 78%) for 2-3 hours; a meal rich in fiber and fruit (e.g., 58% carbohydrates, 15% protein, and 27% fat), as recommended by the American Heart Association, induced no significant change of either LPS or reactive oxygen species.

CharacteristicsRepresentative foodsActive constituentsReferences

Anti-inflammatoryVegetables: avocado, cabbage, carrot, chili pepper, kale, onion, spinach,
Fruit: apple, blueberry, cherry, grape, grapefruit, orange, strawberry, watermelon
Nut: almond, Brazil nuts, cashews, hazelnut, macadamia, peanut, pine nut, pistachio, pecan, walnut
Fish: anchovy, herring, mackerel, salmon, sardine
Other: black pepper,clove, caraway, extra virgin olive oil, flaxseed, green coffee, licorice, nutmeg, oregano, wine (red), sage, tea, thyme
DHA, EPA, capsaicin, carotenoids, curcumin, flavonoids, maresins, monosaturated fats, monoterpenes, omega-3 fatty acids, polyphenols, protectins, quercetin, resolvins, resveratrol, sulfidesKang et al., 2009; Landberg et al., 2011; Mueller et al., 2010; Sears, 2015 [303]; Tsai et al., 2005; Wu & Schauss, 2012 [267], Bolling et al., 2011 [263]; Watzl, 2008

AntioxidantVegetables: beet, beet root, black carrots, cauliflower, chili pepper, garlic, ginger, leek, lettuce, potato, red pepper, turnip, yam
Fruit:  black berry, cherry, strawberry
Nut: pecan
Other: mint, rice bran, turmeric
α-tocopherol, β-carotene, anthocyanins, carotenoids, ellagitannins, flavonoids, lycopene, phytoestrogens, polyphenols, proanthocyanidins, sulfidesKaur & Kapoor, 2002; Tsai et al., 2005; Wu et al., 2004 [347]; Hassan & Abdel-Aziz, 2010; Bolling et al., 2011 [263]; Watzl, 2008; Gülçin, 2012

Typically determined via blood tests for proinflammatory cytokines (IL-6, TNFα, and IL-1), chemokines, acute-phase proteins, cell adhesion molecules, and adipokines [267]; determined via laboratory analyses of the antioxidant activity of food constituents, including phenolic compounds (e.g., flavonoids, isoflavones, and proanthocyanidins), antioxidant vitamins (α-tocopherol, β-carotene), lipids (carotenoids, sterols), total antioxidant capacity (lipophilic plus hydrophilic methods), and/or the oxygen radical absorbance capacity assay [263, 266, 282, 347]. Multianalyte profile technology identifies inflammatory and oxidative biomarkers simultaneously in serum or plasma [348]; also see the US Department of Agriculture database at DHA, docosahexaenoic acid; EPA, eicosapentaenoic acid.

Athletes are quite interested in the potential ergogenic effects of foods and nutritional supplements, to the point that they purposefully alter their diets. These manipulations include carbohydrate loading across several days (i.e., to increase stored glycogen deposits in skeletal muscle and liver tissues), protein supplementation across weeks and months (i.e., to encourage muscle hypertrophy, strength, and recovery, concurrent with heavy resistance training), chronically consuming low-carbohydrate diets (i.e., to induce production of ketones as a fuel during endurance exercise), and weight loss diets which allow athletes to “make weight” in sports with body weight classes [269274]. Unfortunately, these specialized diets may be low in fiber, nonstarch polysaccharides and nondigestible starch [101, 253, 275], which anaerobic bacteria convert into SCFA in the colon. As an example, an animal-based diet (e.g., meats, eggs, and cheeses) decreases the abundance of bacteria in the phylum Firmicutes (Table 2, Figure 1) which metabolize dietary plant polysaccharides [253, 254] and decreases levels of SCFA (i.e., acetate and butyrate) in the gut, compared to a plant-based diet (e.g., grains, legumes, fruits, and vegetables) [258]. Theoretically, this suggests that intestinal functions may be compromised, in ways that are important to exercise performance, including IM effects on colon and liver blood flow, carbohydrate and lipid absorption, energy metabolism, enzyme expression, insulin sensitivity, free fatty acid oxidation, and electrolyte-water absorption in the colon [101103]. In our opinion, the unknown effects of carbohydrate loading, protein supplementation, and low-carbohydrate diets on the IM, intestinal permeability, and plasma LPS levels are worthy of future investigation.

7.3. Antioxidant Supplements

Although a small amount of gastrointestinal permeability and low basal levels of plasma LPS are normal, and a healthy immune system prevents adverse effects, low levels of endotoxin are rapidly removed by inflammatory cells in the liver (Kupffer, macrophages, and neutrophils) [276]. Based on published review articles [277, 278]), research evidence does not support consuming antioxidant supplements when plasma LPS levels are normal. When circulating LPS levels are low, perhaps the only individuals who benefit from antioxidant supplements are those whose habitual diets are antioxidant-deficient. This may be due to the fact that uptake of antioxidant vitamins from supplements is likely to be influenced by the consumption of foods and when one’s diet contains adequate antioxidants (Table 7), the circulation and tissues become saturated [277].

Endurance athletes have elevated plasma LPS antibody (anti-LPS IgG) concentrations at rest [8486, 88] due to repeated, small exposures to LPS that has translocated from the gut during prolonged exercise [88, 94, 96, 97]. Plasma LPS concentration rises when the liver is unable to cope with a large influx of LPS from the intestine; at a greatly exaggerated level, this also occurs in severe EHS cases that involve systemic hypotension, cardiovascular shock, and liver injury [4147]. In these cases, hepatocytes and Kupffer cells are exposed to LPS, proinflammatory cytokine release is stimulated (TNF-α, IL-6), and biochemical reactions generate oxygen free radicals, which have been implicated in various types of acute and chronic liver injury [276]. Free radical oxidative damage occurs in proteins, lipids, cell membranes, mitochondria, and DNA; antioxidant compounds (Table 7) are chemical reducing agents that inhibit the oxidation of other molecules by being oxidized themselves.

Scientists understand much about the complex antioxidant systems and enzymes which plants and animals maintain [279, 280]. However, science has not resolved an interesting paradox regarding antioxidant supplements. Specifically, research evidence from controlled, randomized trials in humans and animals suggest that vitamin E (α-tocopherol), vitamin A (β-carotene), and lycopene supplements provide positive antioxidant effects that diminish biomarkers of liver injury [276, 281283]. These findings suggest, in theory, that antioxidant supplementation encourages efficient liver function, or reduce free radical damage in some disease states. In healthy individuals, large-scale clinical trials (i.e., randomized, double-blind, and placebo-controlled) and meta-analyses of antioxidant supplements have shown either no effect [284, 285] or harmful effects such as an increased risk of prostate cancer [286], hemorrhagic stroke [287], first nonfatal myocardial infarction [288], and mortality [289]. Although several theoretical explanations for this paradox exist [290292], it is clear that additional research is required.

7.4. Amino Acid Supplements

No pharmacologic agent is known to successfully treat fulminant EHS. Amino acid supplements, however, offer a prophylactic approach for possibly preventing/reducing hyperthermia-induced or exercise-induced disruption of the intestinal barrier [293]. Via unknown mechanisms, supplemental glutamine treatment has been shown to reduce or prevent heat-induced intestinal permeability in mice [294], rats [295], and humans [296]. It is possible that glutamine influences this change of permeability by serving as an important fuel source for intestinal enterocytes. Moreover, intestinal permeability was inhibited by pretreatment with arginine supplementation, in mice exercising in a hot environment to a rectal temperature of 39.6°C [297]. Possible protective mechanisms have been proposed, including that glutamine and/or arginine activate immune function, inhibit oxidative stress, stimulate heat shock protein expression, or influence the structure of epithelial cell tight junctions (i.e., ultrastructural bridges that allow LPS translocation from the intestine to plasma) [293295]. Further, it is possible that L-arginine’s role as a precursor to nitric oxide synthesis influences intestinal permeability by modifying blood flow to enterocytes.

7.5. Effects of Diet on Immune Function

Luminal and epithelial immune cells recognize bacterial LPS fragments in the intestine [30]. Because diet influences these immune responses [298, 299], a number of review articles have focused on the negative effects of nutrient deficiencies, malnutrition, and body weight loss [300302], as well as nutrients that are required for effective immune responses. These essential nutrients include amino acids, vitamins (e.g., A, folic acid, B6, B12, C, and E), minerals (e.g., zinc, copper, iron, and selenium) [300], omega-3 polyunsaturated fatty acid in fish oils, and a favorable ratio of omega-3 to omega-6 fatty acids [299, 303, 304]. Further, the reader is reminded that SCFA are products of the fermentation of dietary fiber and complex plant polysaccharides which humans cannot digest (see above). The levels of SCFA in the colon and in blood are important to immunoregulation because they stimulate immune function and resolve inflammation [299]. The concentration of SCFA also affect translocation of microbes [298] and subsequent intensity of immune responses, by enhancing barrier function [265] and decreasing intestinal permeability. Thus, a diet which contains ample vegetables, fruits, and nuts produces important immunomodulatory products.

Prolonged or intense exercise presents unique systemic and cellular demands on the immune system that far exceed those of daily living, in two ways. First, both intense and prolonged exercise bring about a proportional increase in plasma stress hormones (i.e., cortisol, epinephrine, and norepinephrine), which induce changes in immune function (e.g., decreased white blood cell count and increased levels of pro- and anti-inflammatory cytokines) [301, 302]. Second, the increased oxygen free radical formation, which accompanies the dramatic rise of mitochondrial oxidative metabolism during strenuous exercise, potentially could inhibit neutrophil, lymphocyte, and natural killer cell responses [305, 306]. These unique demands suggest that athletes, laborers, or soldiers may require greater quantities of vitamins and minerals with immune-enhancing properties. Unfortunately, the roles of reactive oxygen species during prolonged or intense exercise are unclear, and the endogenous antioxidant defenses in the human body are complex, interlocking, and carefully regulated [290]. Further, the body’s “total antioxidant capacity” seems unresponsive to high doses of dietary antioxidants, so that the amount of oxidative damage to key biomolecules is rarely altered [291]. Given the lack of randomized, placebo-controlled, blinded studies, we encourage researchers to investigate these matters in future human studies that involve dietary influences on immune function, during exercise-heat exposure.

8. Summary

The following factors may alter the IM ecosystem or increase intestinal permeability, plasma LPS, and inflammation: preexisting illness or fever [50, 161, 162], gastroenteritis [161], poor cardiovascular physical fitness [17, 22], lack of heat acclimatization [94, 97], sleep deprivation [116118, 164], prescription medications and drugs of abuse [196, 203, 204], alcoholism [155, 156], NSAID use [46, 179182], and dehydration [122]. Although all of these factors have been recognized previously as predisposing factors for EHS (Table 1), the unique contribution of the present manuscript is the evidence-based focus on their relationships to the IM, endotoxemia, immune function, oxygen free radical injury to tissues, and diet.

Beginning with the premise that restoring or preserving intestinal integrity (i.e., blocking the transfer of LPS from the intestine to general circulation) is a logical step in preventing or attenuating tissue/organ injuries [307], we recommend specific foods that have anti-inflammatory and antioxidant properties. A diet that contains ample vegetables, fruits, and nuts produces important immunomodulatory products which intestinal bacteria metabolize. This dietary plan agrees with the position of the American Dietetic Association [308], the recommendations of the United Nations and World Health Organization [309], and research findings [310, 311]. Although the theoretical connections among these factors are strong, definitive human studies do not exist [263, 268] because the influences of the IM and diet on EHS were not research priorities in years past. We now encourage future research that assesses the IM ecosystem, habitual dietary patterns, plasma LPS, immune function, oxygen free radicals, and biomarkers of inflammation among EHS patients and control subjects. This research should include the purposeful dietary manipulations of athletes, such as carbohydrate loading, protein supplementation, and ketogenic diets which may encourage dysbiosis in the IM ecosystem.

We realize that this research will be complicated by the large interindividual variation of responses (i.e., to exercise-heat stress, diet, and LPS) [29, 312314]; the human genome [129, 315318]; the vast, dynamic IM genome [9, 15, 127, 319]; temporal changes of the IM ecosystem in response to numerous environmental and lifestyle factors (e.g., antibiotics, disease, exercise; [13, 320]); and the fast-acting influence of a single dose of LPS on intestinal permeability [321]. Our incomplete understanding of these complex interactions explains, in part, why EHS cannot be predicted or prevented at present.

Conflicts of Interest

The authors declare that there are no conflicts of interest regarding the publication of this article.


  1. Y. Epstein, “Heat intolerance,” Medicine & Science in Sports & Exercise, vol. 22, no. 1, pp. 29–35, 1990. View at: Publisher Site | Google Scholar
  2. D. J. Casa, J. K. DeMartini, M. F. Bergeron et al., “National Athletic Trainers' Association Position Statement: Exertional Heat Illnesses,” Journal of Athletic Training, vol. 50, pp. 986–1000, 2014. View at: Publisher Site | Google Scholar
  3. American College of Sports Medicine, “American College of Sports Medicine position stand: Exercise and fluid replacement,” Medicine and Science in Sports and Exercise, vol. 39, pp. 377–390, 2007. View at: Google Scholar
  4. L. E. Armstrong and R. W. Hubbard, “Application of a model of exertional heatstroke pathophysiology to cocaine intoxication,” The American Journal of Emergency Medicine, vol. 8, no. 2, p. 178, 1990. View at: Publisher Site | Google Scholar
  5. A. Abriat, C. Brosset, M. Bregigeon, and E. Sagui, “Report of 182 cases of exertional heatstroke in the French Armed Forces,” Military Medicine, vol. 179, no. 3, pp. 309–314, 2015. View at: Publisher Site | Google Scholar
  6. L. R. Leon and B. G. Helwig, “Heat stroke: role of the systemic inflammatory response,” Journal of Applied Physiology, vol. 109, no. 6, pp. 1980–1988, 2010. View at: Publisher Site | Google Scholar
  7. L. E. Armstrong, J. M. Anderson, D. J. Casa, and E. C. Johnson, “Exertional heat stroke and the intestinal microbiome,” Scandinavian Journal of Medicine & Science in Sports, vol. 22, no. 4, pp. 581-582, 2012. View at: Publisher Site | Google Scholar
  8. A. M. O'Hara and F. Shanahan, “The gut flora as a forgotten organ,” EMBO Reports, vol. 7, no. 7, pp. 688–693, 2006. View at: Publisher Site | Google Scholar
  9. E. B. Hollister, C. Gao, and J. Versalovic, “Compositional and functional features of the gastrointestinal microbiome and their effects on human health,” Gastroenterology, vol. 146, no. 6, pp. 1449–1458, 2014. View at: Publisher Site | Google Scholar
  10. P. B. Eckburg, E. M. Bik, C. N. Bernstein et al., “Microbiology: diversity of the human intestinal microbial flora,” Science, vol. 308, no. 5728, pp. 1635–1638, 2005. View at: Publisher Site | Google Scholar
  11. I. Sekirov, S. L. Russell, L. C. Antunes, and B. B. Finlay, “Gut microbiota in health and disease,” Physiological Reviews, vol. 90, no. 3, pp. 859–904, 2010. View at: Publisher Site | Google Scholar
  12. H. Huang, H. B. Krishnan, Q. Pham, L. L. Yu, and T. T. Y. Wang, “Soy and Gut Microbiota: Interaction and Implication for Human Health,” Journal of Agricultural and Food Chemistry, vol. 64, no. 46, pp. 8695–8709, 2016. View at: Publisher Site | Google Scholar
  13. C. A. Lozupone, J. I. Stombaugh, J. I. Gordon, J. K. Jansson, and R. Knight, “Diversity, stability and resilience of the human gut microbiota,” Nature, vol. 489, no. 7415, pp. 220–230, 2012. View at: Publisher Site | Google Scholar
  14. A. Salonen and W. M. De Vos, “Impact of diet on human intestinal microbiota and health,” Annual Review of Food Science and Technology, vol. 5, no. 1, pp. 239–262, 2014. View at: Publisher Site | Google Scholar
  15. E. Le Chatelier, T. Nielsen, and J. Qin, “Richness of human gut microbiome correlates with metabolic markers,” Nature, vol. 500, pp. 541–546, 2013. View at: Publisher Site | Google Scholar
  16. M. J. Claesson, I. B. Jeffery, S. Conde et al., “Gut microbiota composition correlates with diet and health in the elderly,” Nature, vol. 488, no. 7410, pp. 178–184, 2012. View at: Publisher Site | Google Scholar
  17. S. C. Campbell and P. J. Wisniewski, “Exercise is a novel promoter of intestinal health and microbial diversity,” Exercise and Sport Sciences Reviews, vol. 45, no. 1, pp. 41–47, 2017. View at: Publisher Site | Google Scholar
  18. W. R. Russell, S. W. Gratz, S. H. Duncan et al., “High-protein, reduced-carbohydrate weight-loss diets promote metabolite profiles likely to be detrimental to colonic health,” American Journal of Clinical Nutrition, vol. 93, no. 5, pp. 1062–1072, 2011. View at: Publisher Site | Google Scholar
  19. M. I. Queipo-Ortuño, L. M. Seoane, M. Murri et al., “Gut microbiota composition in male rat models under different nutritional status and physical activity and its association with serum leptin and ghrelin levels,” PLoS ONE, vol. 8, no. 5, Article ID e65465, 2013. View at: Publisher Site | Google Scholar
  20. P. J. Turnbaugh, F. Bäckhed, L. Fulton, and J. I. Gordon, “Diet-induced obesity is linked to marked but reversible alterations in the mouse distal gut microbiome,” Cell Host & Microbe, vol. 3, no. 4, pp. 213–223, 2008. View at: Publisher Site | Google Scholar
  21. T. Yatsunenko, F. E. Rey, M. J. Manary et al., “Human gut microbiome viewed across age and geography,” Nature, vol. 486, no. 7402, pp. 222–227, 2012. View at: Publisher Site | Google Scholar
  22. S. F. Clarke, E. F. Murphy, and O. O'Sullivan, “Exercise and associated dietary extremes impact on gut microbial diversity,” Gut, vol. 63, no. 12, pp. 1913–1920, 2014. View at: Publisher Site | Google Scholar
  23. G. L. Hold, “The gut microbiota, dietary extremes and exercise,” Gut, vol. 63, no. 12, pp. 1838-1839, 2014. View at: Publisher Site | Google Scholar
  24. K. T. Kasawara, T. Cotechini, S. K. Macdonald-Goodfellow et al., “Moderate exercise attenuates lipopolysaccharide-induced inflammation and associated maternal and fetal morbidities in pregnant rats,” PLoS ONE, vol. 11, no. 4, Article ID e0154405, 2016. View at: Publisher Site | Google Scholar
  25. J. Olesen, R. S. Biensø, S. Meinertz et al., “Impact of training status on LPS-induced acute inflammation in humans,” Journal of Applied Physiology, vol. 118, no. 7, pp. 818–829, 2015. View at: Publisher Site | Google Scholar
  26. F. W. Booth, C. K. Roberts, and M. J. Laye, “Lack of exercise is a major cause of chronic diseases,” Compr Physiol, vol. 2, no. 2, pp. 1143–211, 2012. View at: Google Scholar
  27. P. Lepage, M. C. Leclerc, M. Joossens et al., “A metagenomic insight into our gut's microbiome,” Gut, vol. 62, no. 1, pp. 146–158, 2013. View at: Publisher Site | Google Scholar
  28. G. L. Simon and S. L. Gorbach, “Intestinal flora in health and disease,” Gastroenterology, vol. 86, no. 1, pp. 174–193, 1984. View at: Google Scholar
  29. R. Burcelin, “Regulation of metabolism: a cross talk between gut microbiota and its human host,” Physiology Journal, vol. 27, no. 5, pp. 300–307, 2012. View at: Publisher Site | Google Scholar
  30. E. J. Schiffrin and S. Blum, “Interactions between the microbiota and the intestinal mucosa,” European Journal of Clinical Nutrition, vol. 56, supplement 3, pp. S60–S64, 2002. View at: Publisher Site | Google Scholar
  31. G. P. Lambert, C. V. Gisolfi, D. J. Berg, P. L. Moseley, L. W. Oberley, and K. C. Kregel, “Selected contribution: hyperthermia-induced intestinal permeability and the role of oxidative and nitrosative stress,” Journal of Applied Physiology, vol. 92, no. 4, pp. 1750–1761, 2002. View at: Publisher Site | Google Scholar
  32. G. P. Lambert, “Role of gastrointestinal permeability in exertional heatstroke,” Exercise and Sport Sciences Reviews, vol. 32, no. 4, pp. 185–190, 2004. View at: Publisher Site | Google Scholar
  33. S. P. Treon, P. Thomas, and S. A. Broitman, “Lipopolysaccharide (LPS) Processing by Kupffer Cells releases a modified LPS with increased Hepatocyte binding and decreased tumor Necrosis factor-α Stimulatory capacity,” Proceedings of the Society for Experimental Biology and Medicine, vol. 202, no. 2, pp. 153–158, 1993. View at: Publisher Site | Google Scholar
  34. G. P. Lambert, “Intestinal barrier dysfunction, endotoxemia, and gastrointestinal symptoms: The "canary in the coal mine" during exercise-heat stress?” Medicine and Sport Science, vol. 53, pp. 61–73, 2008. View at: Publisher Site | Google Scholar
  35. C. Erridge, T. Attina, C. M. Spickett, and D. J. Webb, “A high-fat meal induces low-grade endotoxemia: evidence of a novel mechanism of postprandial inflammation,” The American Journal of Clinical Nutrition, vol. 86, no. 5, pp. 1286–92, 2007. View at: Google Scholar
  36. R. Barone, F. Macaluso, C. Sangiorgi et al., “Skeletal muscle Heat shock protein 60 increases after endurance training and induces peroxisome proliferator-activated receptor gamma coactivator 1 α1 expression,” Scientific Reports, vol. 6, Article ID 19781, 2016. View at: Publisher Site | Google Scholar
  37. P. Rallabhandi, A. Awomoyi, K. E. Thomas et al., “Differential activation of human TLR4 by Escherichia coli and Shigella flexneri 2a lipopolysaccharide: Combined effects of lipid a acylation state and TLR4 polymorphisms on signaling,” The Journal of Immunology, vol. 180, no. 2, pp. 1139–1147, 2008. View at: Publisher Site | Google Scholar
  38. N. Maeshima and R. C. Fernandez, “Recognition of lipid A variants by the TLR4-MD-2 receptor complex,” Frontiers in Cellular and Infection Microbiology, vol. 4, Article ID Article 3, 2013. View at: Publisher Site | Google Scholar
  39. L. Yang, H. Guo, Y. Li et al., “Oleoylethanolamide exerts anti-inflammatory effects on LPS-induced THP-1 cells by enhancing PPARα signaling and inhibiting the NF-κB and ERK1/2/AP-1/STAT3 pathways,” Scientific Reports, vol. 6, Article ID 34611, 2016. View at: Publisher Site | Google Scholar
  40. P. D. Cani and N. M. Delzenne, “The gut microbiome as therapeutic target,” Pharmacology & Therapeutics, vol. 130, no. 2, pp. 202–212, 2011. View at: Publisher Site | Google Scholar
  41. E. Assia, Y. Epstein, and Y. Shapiro, “Fatal heatstroke after a short march at night: A case report,” Aviation, Space, and Environmental Medicine, vol. 56, no. 5, pp. 441-442, 1985. View at: Google Scholar
  42. A. Bouchama, G. Roberts, F. Al Mohanna et al., “Inflammatory, hemostatic, and clinical changes in a baboon experimental model for heatstroke,” Journal of Applied Physiology, vol. 98, no. 2, pp. 697–705, 2005. View at: Publisher Site | Google Scholar
  43. S. L. Gaffin and R. W. Hubbard, “Pathophysiology of heatstroke,” in Medical aspects of harsh environments, pp. 195–208, 2001, Officer of the Surgeon General, U.S. Army. View at: Google Scholar
  44. A. Bouchama and J. P. Knochel, “Heat stroke,” The New England Journal of Medicine, vol. 346, no. 25, pp. 1978–1988, 2002. View at: Publisher Site | Google Scholar
  45. D. M. Hall, G. R. Buettner, L. W. Oberley, L. Xu, R. D. Matthes, and C. V. Gisolfi, “Mechanisms of circulatory and intestinal barrier dysfunction during whole body hyperthermia,” American Journal of Physiology-Heart and Circulatory Physiology, vol. 280, no. 2, pp. H509–H521, 2001. View at: Publisher Site | Google Scholar
  46. G. P. Lambert, L. J. Broussard, B. L. Mason, W. J. Mauermann, and C. V. Gisolfi, “Gastrointestinal permeability during exercise: Effects of aspirin and energy-containing beverages,” Journal of Applied Physiology, vol. 90, no. 6, pp. 2075–2080, 2001. View at: Publisher Site | Google Scholar
  47. M. Singer, C. S. Deutschman, C. W. Seymour et al., “The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3),” JAMA, vol. 315, no. 8, pp. 801–810, 2016. View at: Google Scholar
  48. L. D. Maclean and M. H. Weil, “Hypotension (Shock) in Dogs produced by Escherichia coli endotoxin,” Circulation Research, vol. 4, no. 5, pp. 546–556, 1956. View at: Publisher Site | Google Scholar
  49. T. C. Chao, R. Sinniah, and J. E. Pakiam, “Acute heat stroke deaths,” Pathology, vol. 13, no. 1, pp. 145–156, 1981. View at: Publisher Site | Google Scholar
  50. M. Rav-Acha, E. Hadad, Y. Epstein, Y. Heled, and D. S. Moran, “Fatal exertional heart stroke: A case series,” The American Journal of the Medical Sciences, vol. 328, no. 2, pp. 84–87, 2004. View at: Publisher Site | Google Scholar
  51. S. Shibolet, M. C. Lancaster, and Y. Danon, “Heat stroke: a review,” Aviation, Space, and Environmental Medicine, vol. 47, no. 3, pp. 280–301, 1976. View at: Google Scholar
  52. N. Miron and V. Cristea, “Enterocytes: active cells in tolerance to food and microbial antigens in the gut,” Clinical & Experimental Immunology, vol. 167, no. 3, pp. 405–412, 2012. View at: Publisher Site | Google Scholar
  53. S. Lange and D. S. Delbro, “Adrenoceptor-mediated modulation of evans blue dye permeation of rat small intestine,” Digestive Diseases and Sciences, vol. 40, no. 12, pp. 2623–2629, 1995. View at: Publisher Site | Google Scholar
  54. J. B. Meddings and M. G. Swain, “Environmental stress-induced gastrointestinal permeability is mediated by endogenous glucocorticoids in the rat,” Gastroenterology, vol. 119, no. 4, pp. 1019–1028, 2000. View at: Publisher Site | Google Scholar
  55. T. Vanuytsel, S. van Wanrooy, H. Vanheel et al., “Psychological stress and corticotropin-releasing hormone increase intestinal permeability in humans by a mast cell-dependent mechanism,” Gut, vol. 63, no. 8, pp. 1293–1299, 2014. View at: Publisher Site | Google Scholar
  56. P.-C. Yang, S.-H. He, and P.-Y. Zheng, “Investigation into the signal transduction pathway via which heat stress impairs intestinal epithelial barrier function,” Journal of Gastroenterology and Hepatology, vol. 22, no. 11, pp. 1823–1831, 2007. View at: Publisher Site | Google Scholar
  57. S. Varasteh, S. Braber, P. Akbari, J. Garssen, and J. Fink-Gremmels, “Differences in susceptibility to heat stress along the chicken intestine and the protective effects of galacto- oligosaccharides,” PLoS ONE, vol. 10, no. 9, Article ID e0138975, 2015. View at: Publisher Site | Google Scholar
  58. M. N. Zuhl, K. R. Lanphere, L. Kravitz et al., “Effects of oral glutamine supplementation on exercise-induced gastrointestinal permeability and tight junction protein expression,” Journal of Applied Physiology, vol. 116, no. 2, pp. 183–191, 2014. View at: Publisher Site | Google Scholar
  59. K. Dokladny, P. L. Moseley, and T. Y. Ma, “Physiologically relevant increase in temperature causes an increase in intestinal epithelial tight junction permeability,” American Journal of Physiology-Gastrointestinal and Liver Physiology, vol. 290, no. 2, pp. G204–G212, 2006. View at: Publisher Site | Google Scholar
  60. J. R. Turner, “Intestinal mucosal barrier function in health and disease,” Nature Reviews Immunology, vol. 9, no. 11, pp. 799–809, 2009. View at: Publisher Site | Google Scholar
  61. Y. Heled, C. Fleischmann, and Y. Epstein, “Cytokines and their role in hyperthermia and heat stroke,” Journal of Basic and Clinical Physiology and Pharmacology, vol. 24, no. 2, pp. 85–96, 2013. View at: Publisher Site | Google Scholar
  62. P. Gathiram, M. T. Wells, J. G. Brock-Utne, and S. L. Gaffin, “Antilipopolysaccharide improves survival in primates subjected to heat stroke,” Circ Shock, vol. 23, no. 3, pp. 157–64, 1987. View at: Google Scholar
  63. P. Gathiram, M. T. Wells, J. G. Brock-Utne, B. C. Wessels, and S. L. Gaffin, “Prevention of endotoxaemia by non-absorbable antibiotics in heat stress,” Journal of Clinical Pathology, vol. 40, no. 11, pp. 1364–1368, 1987. View at: Publisher Site | Google Scholar
  64. G. Bynum, J. Brown, D. Dubose, and B. Lee Caleb, “Increased survival in experimental dog heatstroke after reduction of gut flora,” Aviat Space Environ Med, vol. 50, no. 8, p. 816, 1979. View at: Google Scholar
  65. K. J. Tracey, Y. Fong, D. G. Hesse et al., “Anti-cachectin/TNF monoclonal antibodies prevent septic shock during lethal bacteraemia,” Nature, vol. 330, no. 6149, pp. 662–664, 1987. View at: Publisher Site | Google Scholar
  66. C. L. Lim and K. Suzuki, “Systemic Inflammation Mediates the Effects of Endotoxemia in the Mechanisms of Heat Stroke,” Biology and Medicine, vol. 09, no. 01, 2017. View at: Publisher Site | Google Scholar
  67. K. X. Mulligan, R. T. Morris, Y. F. Otero, D. H. Wasserman, and O. P. McGuinness, “Disassociation of muscle insulin signaling and insulin-stimulated glucose uptake during endotoxemia,” PLoS ONE, vol. 7, no. 1, Article ID e30160, 2012. View at: Publisher Site | Google Scholar
  68. C. D. Graber, R. B. Reinhold, J. G. Breman, R. A. Harley, and G. R. Hennigar, “Fatal Heat Stroke: Circulating Endotoxin and Gram-Negative Sepsis as Complications,” Journal of the American Medical Association, vol. 216, no. 7, pp. 1195-1196, 1971. View at: Publisher Site | Google Scholar
  69. A. Bouchama, R. S. Parhar, A. El-Yazigi, K. Sheth, and S. Al-Sedairy, “Endotoxemia and release of tumor necrosis factor and interleukin 1α in acute heatstroke,” Journal of Applied Physiology, vol. 70, no. 6, pp. 2640–2644, 1991. View at: Publisher Site | Google Scholar
  70. P. Gathiram, M. T. Wells, D. Raidoo, J. G. Brock-Utne, and S. L. Gaffin, “Portal and systemic plasma lipopolysaccharide concentrations in heat-stressed primates,” Circ Shock, vol. 25, no. 3, pp. 223–30, 1988. View at: Google Scholar
  71. P. A. M. van Leeuwen, M. A. Boermeester, A. P. J. Houdijk et al., “Clinical significance of translocation,” Gut, vol. 35, supplement 1, pp. S28–S34, 1994. View at: Google Scholar
  72. L. Hermansen and J. B. Osnes, “Blood and muscle pH after maximal exercise in man,” Journal of Applied Physiology, vol. 32, no. 3, pp. 304–308, 1972. View at: Publisher Site | Google Scholar
  73. H. B. Nielsen, L. B. Svendsen, T. H. Jensen, and N. H. Secher, “Exercise-induced gastric mucosal acidosis,” Medicine & Science in Sports & Exercise, vol. 27, no. 7, pp. 1003–1006, 1995. View at: Publisher Site | Google Scholar
  74. R. W. Hubbard and L. E. Armstrong, “The heat illnesses: biochemical ultrastructural, and fluid-electrolyte considerations,” in Human performance physiology and environmental medicine at terrestrial extremes, K. B. Pandolf, M. N. Sawka, and R. R. Gonzalez, Eds., pp. 199–226, Indianapolis: Benchmark Press, 1988. View at: Google Scholar
  75. N. Unno, M. J. Menconi, A. L. Salzman et al., “Hyperpermeability and ATP depletion induced by chronic hypoxia or glycolytic inhibition in Caco-2BBe monolayers,” American Journal of Physiology-Gastrointestinal and Liver Physiology, vol. 270, no. 6, pp. G1010–G1021, 1996. View at: Publisher Site | Google Scholar
  76. R. W. Hubbard, “Heatstroke pathophysiology: the energy depletion mode,” Med Sci Sports Exerc, vol. 22, pp. 19–28, 1990. View at: Google Scholar
  77. M. J. Menconi, A. L. Salzman, N. Unno et al., “Acidosis induces hyperpermeability in Caco-2BBe cultured intestinal epithelial monolayers,” American Journal of Physiology-Gastrointestinal and Liver Physiology, vol. 272, no. 5, pp. G1007–G1021, 1997. View at: Publisher Site | Google Scholar
  78. C. L. Sprung and M. J. Hauser, “Heatstroke,” The Lancet, vol. 2, no. 8195, p. 642, 1980. View at: Google Scholar
  79. A. Bouchama and E. B. De Vol, “Acid-base alterations in heatstroke,” Intensive Care Medicine, vol. 27, no. 4, pp. 680–685, 2001. View at: Publisher Site | Google Scholar
  80. G. R. Hart, R. J. Anderson, C. P. Crumpler, A. Shulkin, G. Reed, and J. P. Knochel, “Epidemic Classical Heat Stroke,” Medicine, vol. 61, no. 3, p. 189, 1982. View at: Publisher Site | Google Scholar
  81. K. C. Kregel, P. T. Wall, and C. V. Gisolfi, “Peripheral vascular responses to hyperthermia in the rat,” Journal of Applied Physiology, vol. 64, no. 6, pp. 2582–2588, 1988. View at: Publisher Site | Google Scholar
  82. Y. Epstein, W. O. Roberts, R. Golan, Y. Heled, P. Sorkine, and P. Halpern, “Sepsis, septic shock, and fatal exertional heat stroke,” Current Sports Medicine Reports, vol. 14, no. 1, pp. 64–69, 2015. View at: Publisher Site | Google Scholar
  83. H.-L. Alakomi, E. Skyttä, M. Saarela, T. Mattila-Sandholm, K. Latva-Kala, and I. M. Helander, “Lactic acid permeabilizes gram-negative bacteria by disrupting the outer membrane,” Applied and Environmental Microbiology, vol. 66, no. 5, pp. 2001–2005, 2000. View at: Publisher Site | Google Scholar
  84. A. E. Jeukendrup, K. Vet-Joop, A. Sturk et al., “Relationship between gastro-intestinal complaints and endotoxaemia, cytokine release and the acute-phase reaction during and after a long-distance triathlon in highly trained men,” Clinical Science, vol. 98, no. 1, pp. 47–55, 2000. View at: Publisher Site | Google Scholar
  85. G. Camus, J. Poortmans, M. Nys et al., “Mild endotoxaemia and the inflammatory response induced by a marathon race,” Clinical Science, vol. 92, no. 4, pp. 415–422, 1997. View at: Publisher Site | Google Scholar
  86. J. G. Brock-Utne, S. L. Gaffin, M. T. Wells et al., “Endotoxaemia in exhausted runners after a long-distance race,” South African Medical Journal, vol. 73, no. 9, p. 533, 1988. View at: Google Scholar
  87. K. L. Pals, R.-T. Chang, A. J. Ryan, and C. V. Gisolfi, “Effect of running intensity on intestinal permeability,” Journal of Applied Physiology, vol. 82, no. 2, pp. 571–576, 1997. View at: Publisher Site | Google Scholar
  88. A. T. Bosenberg, J. G. Brock-Utne, S. L. Gaffin, M. T. B. Wells, and G. T. W. Blake, “Strenuous exercise causes systemic endotoxemia,” Journal of Applied Physiology, vol. 65, no. 1, pp. 106–108, 1988. View at: Publisher Site | Google Scholar
  89. M. J. Perko, H. B. Nielsen, C. Skak, J. O. Clemmesen, T. V. Schroeder, and N. H. Secher, “Mesenteric, coeliac and splanchnic blood flow in humans during exercise,” The Journal of Physiology, vol. 513, no. 3, pp. 907–913, 1998. View at: Publisher Site | Google Scholar
  90. L. B. Rowell, G. L. Brengelmann, J. R. Blackmon, R. D. Twiss, and F. Kusumi, “Splanchnic blood flow and metabolism in heat-stressed man.,” Journal of Applied Physiology, vol. 24, no. 4, pp. 475–484, 1968. View at: Publisher Site | Google Scholar
  91. K. van Wijck, K. Lenaerts, L. J. C. van Loon, W. H. M. Peters, W. A. Buurman, and C. H. C. Dejong, “Exercise-induced splanchnic hypoperfusion results in gut dysfunction in healthy men,” PLoS ONE, vol. 6, no. 7, Article ID e22366, 2011. View at: Publisher Site | Google Scholar
  92. G. A. Selkirk, T. M. McLellan, H. E. Wright, and S. G. Rhind, “Mild endotoxemia, NF-κB translocation, and cytokine increase during exertional heat stress in trained and untrained individuals,” American Journal of Physiology-Regulatory, Integrative and Comparative Physiology, vol. 295, no. 2, pp. R611–R623, 2008. View at: Publisher Site | Google Scholar
  93. A. Marino, F. Pellegrini, and A. M. Lucchesi, “Multiorgan damage in exertion heatstroke,” Minerva Anestesiol, vol. 58, no. 6, pp. 393–395, 1992. View at: Google Scholar
  94. S. Sakurada and J. R. S. Hales, “A role for gastrointestinal endotoxins in enhancement of heat tolerance by physical fitness,” Journal of Applied Physiology, vol. 84, no. 1, pp. 207–214, 1998. View at: Publisher Site | Google Scholar
  95. A. E. Medvedev, W. Piao, J. Shoenfelt et al., “Role of TLR4 tyrosine phosphorylation in signal transduction and endotoxin tolerance,” The Journal of Biological Chemistry, vol. 282, no. 22, pp. 16042–16053, 2007. View at: Publisher Site | Google Scholar
  96. C. L. Lim, D. Pyne, P. Horn et al., “The effects of increased endurance training load on biomarkers of heat intolerance during intense exercise in the heat,” Applied Physiology, Nutrition, and Metabolism, vol. 34, no. 4, pp. 616–624, 2009. View at: Publisher Site | Google Scholar
  97. R. L. Starkie, M. Hargreaves, J. Rolland, and M. A. Febbraio, “Heat stress, cytokines, and the immune response to exercise,” Brain, Behavior, and Immunity, vol. 19, no. 5, pp. 404–412, 2005. View at: Publisher Site | Google Scholar
  98. Y. J. Hsu, C. C. Chiu, Y. P. Li et al., “Effect of intestinal microbiota on exercise performance in mice,” The Journal of Strength and Conditioning Research, vol. 29, no. 2, pp. 552–558, 2015. View at: Publisher Site | Google Scholar
  99. A. Sureda, P. Tauler, A. Aguiló et al., “Relation between oxidative stress markers and antioxidant endogenous defences during exhaustive exercise,” Free Radical Research, vol. 39, no. 12, pp. 1317–1324, 2005. View at: Publisher Site | Google Scholar
  100. C. M. Deaton and D. J. Marlin, “Exercise-associated oxidative stress,” Clinical Techniques in Equine Practice, vol. 2, no. 3, pp. 278–291, 2003. View at: Publisher Site | Google Scholar
  101. A. Clark and N. Mach, “Exercise-induced stress behavior, gut-microbiota-brain axis and diet: A systematic review for athletes,” Journal of the International Society of Sports Nutrition, vol. 13, no. 1, article no. 43, 2016. View at: Publisher Site | Google Scholar
  102. J. A. Hawrelak and S. P. Myers, “The causes of intestinal dysbiosis: a review,” Alternative Medicine Review, vol. 9, no. 2, pp. 180–197, 2004. View at: Google Scholar
  103. G. Musso, R. Gambino, and M. Cassader, “Interactions between gut microbiota and host metabolism predisposing to obesity and diabetes,” Annual Review of Medicine, vol. 62, pp. 361–380, 2011. View at: Publisher Site | Google Scholar
  104. L. E. Armstrong and C. M. Maresh, “The Induction and Decay of Heat Acclimatisation in Trained Athletes,” Sports Medicine, vol. 12, no. 5, pp. 302–312, 1991. View at: Publisher Site | Google Scholar
  105. F. Amorim, P. Yamada, R. Robergs, S. Schneider, and P. Moseley, “Effects of whole-body heat acclimation on cell injury and cytokine responses in peripheral blood mononuclear cells,” European Journal of Applied Physiology, vol. 111, no. 8, pp. 1609–1618, 2011. View at: Publisher Site | Google Scholar
  106. L. L. Hom, E. C.-H. Lee, J. M. Apicella et al., “Eleven days of moderate exercise and heat exposure induces acclimation without significant HSP70 and apoptosis responses of lymphocytes in college-aged males,” Cell Stress and Chaperones, vol. 17, no. 1, pp. 29–39, 2012. View at: Publisher Site | Google Scholar
  107. H. Northoff, C. Weinstock, and A. Berg, “The cytokine response to strenuous exercise,” International Journal of Sports Medicine, vol. 15, no. 3, pp. S167–S171, 1994. View at: Publisher Site | Google Scholar
  108. B. K. Pedersen, K. Ostrowski, T. Rohde, and H. Bruunsgaard, “The cytokine response to strenuous exercise,” Canadian Journal of Physiology and Pharmacology, vol. 76, no. 5, pp. 505–511, 1998. View at: Publisher Site | Google Scholar
  109. E. T. Cunningham and E. B. De Souza, “Interleukin 1 receptors in the brain and endocrine tissues,” Trends in Immunology, vol. 14, no. 4, pp. 166–170, 1993. View at: Publisher Site | Google Scholar
  110. M. R. Opp, E. M. Smith, and T. K. Hughes Jr., “Interleukin-10 (cytokine synthesis inhibitory factor) acts in the central nervous system of rats to reduce sleep,” Journal of Neuroimmunology, vol. 60, no. 1-2, pp. 165–168, 1995. View at: Publisher Site | Google Scholar
  111. H. Moldofsky, F. A. Lue, J. R. Davidson, and R. Gorczynski, “Effects of sleep deprivation on human immune functions,” The FASEB Journal, vol. 3, no. 8, pp. 1972–1977, 1989. View at: Publisher Site | Google Scholar
  112. J. Palmblad, B. Petrini, J. Wasserman, and T. Akerstedt, “Lymphocyte and granulocyte reactions dueing sleep deprivation,” Psychosomatic Medicine, vol. 41, no. 4, pp. 273–278, 1979. View at: Publisher Site | Google Scholar
  113. L. A. Toth, E. A. Tolley, and J. M. Krueger, “Sleep as a Prognostic Indicator During Infectious Disease in Rabbits,” Proceedings of the Society for Experimental Biology and Medicine, vol. 203, no. 2, pp. 179–192, 1993. View at: Publisher Site | Google Scholar
  114. P. Naitoh, T. L. Kelly, and C. Englund, “Health effects of sleep deprivation,” Occup Med, vol. 5, no. 2, pp. 209–37, 1990. View at: Google Scholar
  115. E. D. Luby, C. E. Frohman, J. L. Grisell, J. E. Lenzo, and J. S. Gottlieb, “Sleep deprivation: effects on behavior, thinking, motor performance, and biological energy transfer systems,” Psychosomatic Medicine, vol. 22, no. 3, pp. 182–192, 1960. View at: Publisher Site | Google Scholar
  116. C. A. Everson and L. A. Toth, “Systemic bacterial invasion induced by sleep deprivation,” American Journal of Physiology-Regulatory, Integrative and Comparative Physiology, vol. 278, no. 4, pp. R905–R916, 2000. View at: Publisher Site | Google Scholar
  117. C. A. Everson, “Sustained sleep deprivation impairs host defense,” American Journal of Physiology-Regulatory, Integrative and Comparative Physiology, vol. 265, no. 5, pp. R1148–R1154, 1993. View at: Publisher Site | Google Scholar
  118. E. A. Deitch, D. Xu, L. Franko, A. Ayala, and I. H. Chaudry, “Evidence favoring the role of the gut as a cytokine-generating organ in rats subjected to hemorrhagic shock,” Shock, vol. 1, no. 2, pp. 141–145, 1994. View at: Publisher Site | Google Scholar
  119. Y. Epstein and W. O. Roberts, “The pathopysiology of heat stroke: an integrative view of the final common pathway,” Scandinavian Journal of Medicine & Science in Sports, vol. 21, no. 6, pp. 742–748, 2011. View at: Publisher Site | Google Scholar
  120. L. R. Leon, “Heat stroke and cytokines,” Progress in Brain Research, vol. 162, pp. 481–524, 2007. View at: Publisher Site | Google Scholar
  121. L. L. Chin and L. T. Mackinnon, “The roles of exercise-induced immune system disturbances in the pathology of heat stroke: the dual pathway model of heat stroke,” Sports Medicine, vol. 36, no. 1, pp. 39–64, 2006. View at: Publisher Site | Google Scholar
  122. G. P. Lambert, J. Lang, A. Bull et al., “Fluid restriction during running increases GI permeability,” International Journal of Sports Medicine, vol. 29, no. 3, pp. 194–198, 2008. View at: Publisher Site | Google Scholar
  123. M. J. Dorresteijn, L. T. van Eijk, M. G. Netea, P. Smits, J. G. van der Hoeven, and P. Pickkers, “Iso-osmolar prehydration shifts the cytokine response towards a more anti-inflammatory balance in human endotoxemia,” Journal of Endotoxin Research, vol. 11, no. 5, pp. 287–293, 2005. View at: Publisher Site | Google Scholar
  124. L. Hannemann, K. Reinhart, R. Korell, C. Spies, and D. L. Bredle, “Hypertonic saline in stabilized hyperdynamic sepsis,” Shock, vol. 5, no. 2, pp. 130–134, 1996. View at: Publisher Site | Google Scholar
  125. R. P. Oliveira, R. Weingartner, E. O. Ribas, R. S. Moraes, and G. Friedman, “Acute haemodynamic effects of a hypertonic saline/dextran solution in stable patients with severe sepsis,” Intensive Care Medicine, vol. 28, no. 11, pp. 1574–1581, 2002. View at: Publisher Site | Google Scholar
  126. G. Corthier and J. Doré, “A new era in gut research concerning interactions between microbiota and human health,” Gastroentérologie Clinique et Biologique, vol. 34, no. 1, pp. S1–S6, 2010. View at: Publisher Site | Google Scholar
  127. J. L. Sonnenburg, J. Xu, D. D. Leip et al., “Glycan foraging in vivo by an intestine-adapted bacterial symbiont,” Science, vol. 307, no. 5717, pp. 1955–1959, 2005. View at: Publisher Site | Google Scholar
  128. F. Bäckhed, R. E. Ley, J. L. Sonnenburg, D. A. Peterson, and J. I. Gordon, “Host-bacterial mutualism in the human intestine,” Science, vol. 307, no. 5717, pp. 1915–1920, 2005. View at: Publisher Site | Google Scholar
  129. A. W. Walker, J. Ince, S. H. Duncan et al., “Dominant and diet-responsive groups of bacteria within the human colonic microbiota,” The ISME Journal, vol. 5, no. 2, pp. 220–230, 2011. View at: Publisher Site | Google Scholar
  130. J. R. Brestoff and D. Artis, “Commensal bacteria at the interface of host metabolism and the immune system,” Nature Immunology, vol. 14, no. 7, pp. 676–684, 2013. View at: Publisher Site | Google Scholar
  131. P. Louis, K. P. Scott, S. H. Duncan, and H. J. Flint, “Understanding the effects of diet on bacterial metabolism in the large intestine,” Journal of Applied Microbiology, vol. 102, no. 5, pp. 1197–1208, 2007. View at: Publisher Site | Google Scholar
  132. Y. Shapiro and D. S. Seidman, “Field and clinical observations of exertional heat stroke patients,” Medicine & Science in Sports & Exercise, vol. 22, no. 1, pp. 6–14, 1990. View at: Publisher Site | Google Scholar
  133. H. Shapiro, C. A. Thaiss, M. Levy, and E. Elinav, “The cross talk between microbiota and the immune system: Metabolites take center stage,” Current Opinion in Immunology, vol. 30, no. 1, pp. 54–62, 2014. View at: Publisher Site | Google Scholar
  134. M. Nieuwdorp, P. W. Gilijamse, N. Pai, and L. M. Kaplan, “Role of the microbiome in energy regulation and metabolism,” Gastroenterology, vol. 146, no. 6, pp. 1525–1533, 2014. View at: Publisher Site | Google Scholar
  135. J. K. Nicholson, E. Holmes, J. Kinross et al., “Host-gut microbiota metabolic interactions,” Science, vol. 336, no. 6086, pp. 1262–1267, 2012. View at: Publisher Site | Google Scholar
  136. P. D. Cani, R. Bibiloni, C. Knauf et al., “Changes in gut microbiota control metabolic endotoxemia-induced inflammation in high-fat diet-induced obesity and diabetes in mice,” Diabetes, vol. 57, no. 6, pp. 1470–1481, 2008. View at: Publisher Site | Google Scholar
  137. M. Membrez, F. Blancher, M. Jaquet et al., “Gut microbiota modulation with norfloxacin and ampicillin enhances glucose tolerance in mice,” The FASEB Journal, vol. 22, no. 7, pp. 2416–2426, 2008. View at: Publisher Site | Google Scholar
  138. P. Brun, I. Castagliuolo, V. Di Leo et al., “Increased intestinal permeability in obese mice: new evidence in the pathogenesis of nonalcoholic steatohepatitis,” American Journal of Physiology-Gastrointestinal and Liver Physiology, vol. 292, no. 2, pp. G518–G525, 2007. View at: Publisher Site | Google Scholar
  139. I. Pappo, H. Becovier, E. M. Berry, and H. R. Freund, “Polymyxin B reduces cecal flora, TNF production and hepatic steatosis during total parenteral nutrition in the rat,” Journal of Surgical Research, vol. 51, no. 2, pp. 106–112, 1991. View at: Publisher Site | Google Scholar
  140. H. Ghanim, S. Abuaysheh, C. L. Sia et al., “Increase in plasma endotoxin concentrations and the expression of toll-like receptors and suppressor of cytokine signaling-3 in mononuclear cells after a high-fat, high-carbohydrate meal: implications for insulin resistance,” Diabetes Care, vol. 32, no. 12, pp. 2281–2287, 2009. View at: Publisher Site | Google Scholar
  141. S. Dogan, M. Celikbilek, and K. Guven, “High fructose consumption can induce endotoxemia,” Gastroenterology, vol. 143, no. 3, p. e29, 2012. View at: Publisher Site | Google Scholar
  142. J. Amar, R. Burcelin, and J. B. Ruidavets, “Energy intake is associated with endotoxemia in apparently healthy men,” The American Journal of Clinical Nutrition, vol. 87, no. 5, pp. 1219–1223, 2008. View at: Google Scholar
  143. R. Deopurkar, H. Ghanim, J. Friedman et al., “Differential effects of cream, glucose, and orange juice on inflammation, endotoxin, and the expression of toll-like receptor-4 and suppressor of cytokine signaling-3,” Diabetes Care, vol. 33, no. 5, pp. 991–997, 2010. View at: Publisher Site | Google Scholar
  144. S. Ghoshal, J. Witta, J. Zhong, W. de Villiers, and E. Eckhardt, “Chylomicrons promote intestinal absorption of lipopolysaccharides,” Journal of Lipid Research, vol. 50, no. 1, pp. 90–97, 2009. View at: Publisher Site | Google Scholar
  145. F. Laugerette, C. Vors, A. Géloën et al., “Emulsified lipids increase endotoxemia: possible role in early postprandial low-grade inflammation,” The Journal of Nutritional Biochemistry, vol. 22, no. 1, pp. 53–59, 2011. View at: Publisher Site | Google Scholar
  146. P. D. Anderson, N. N. Mehta, M. L. Wolfe et al., “Innate Immunity Modulates Adipokines in Humans,” The Journal of Clinical Endocrinology & Metabolism, vol. 92, no. 6, pp. 2272–2279, 2007. View at: Publisher Site | Google Scholar
  147. X.-J. Lin, Y.-J. Li, Z.-L. Li, F. Zou, and M.-T. Lin, “Pre-existing lipopolysaccharide may increase the risk of heatstroke in rats,” The American Journal of the Medical Sciences, vol. 337, no. 4, pp. 265–270, 2009. View at: Publisher Site | Google Scholar
  148. C. M. Blatteis and E. Sehic, “Fever: how may circulating pyrogens signal the brain?” News in Physiological Sciences, vol. 12, no. 1, pp. 1–9, 1997. View at: Google Scholar
  149. E. Zeisberger, E. Schönbaum, and P. Lomax, Thermal Balance in Health and Disease, Birkhäuser Basel, Basel, 1994. View at: Publisher Site
  150. Z. Xing, T. Braciak, and M. Jordana, “Adenovirus-mediated cytokine gene transfer at tissue sites. Overexpression of IL-6 induces lymphocytic hyperplasia in the lung,” Journal of Immunology, vol. 153, no. 9, pp. 4059–69, 1994. View at: Google Scholar
  151. C. Gabay, “Interleukin-6 and chronic inflammation,” Arthritis Research & Therapy, vol. 8, article S3, supplement 2, 2006. View at: Publisher Site | Google Scholar
  152. D. N. Frank, A. L. S. Amand, R. A. Feldman, E. C. Boedeker, N. Harpaz, and N. R. Pace, “Molecular-phylogenetic characterization of microbial community imbalances in human inflammatory bowel diseases,” Proceedings of the National Acadamy of Sciences of the United States of America, vol. 104, no. 34, pp. 13780–13785, 2007. View at: Publisher Site | Google Scholar
  153. P. D. Cani, J. Amar, and M. A. Iglesias, “Metabolic endotoxemia initiates obesity and insulin resistance,” Diabetes, vol. 56, no. 7, pp. 1761–1772, 2007. View at: Google Scholar
  154. M. A. Azcárate-Peril, M. Sikes, and J. M. Bruno-Bárcena, “The intestinal microbiota, gastrointestinal environment and colorectal cancer: a putative role for probiotics in prevention of colorectal cancer?” American Journal of Physiology-Gastrointestinal and Liver Physiology, vol. 301, no. 3, pp. G401–G424, 2011. View at: Publisher Site | Google Scholar
  155. P. Hartmann, W.-C. Chen, and B. Schnabl, “The intestinal microbiome and the leaky gut as therapeutic targets in alcoholic liver disease,” Frontiers in Physiology, vol. 3, Article ID Article 402, 2012. View at: Publisher Site | Google Scholar
  156. S. Patel, R. Behara, G. R. Swanson, C. B. Forsyth, R. M. Voigt, and A. Keshavarzian, “Alcohol and the intestine,” Biomolecules, vol. 5, no. 4, pp. 2573–2588, 2015. View at: Publisher Site | Google Scholar
  157. N. Enomoto, K. Ikejima, S. Yamashina et al., “Kupffer cell sensitization by alcohol involves increased permeability to gut-derived Endotoxin,” Alcoholism: Clinical and Experimental Research, vol. 25, no. s2, pp. 51S–54S, 2001. View at: Publisher Site | Google Scholar
  158. P. A. Engen, “The gastrointestinal microbiome: alcohol effects on the composition of intestinal microbiota,” Alcohol Res, vol. 37, no. 2, pp. 223–36, 2015. View at: Google Scholar
  159. J. P. Knochel, “Environmental Heat Illness: An Eclectic Review,” JAMA Internal Medicine, vol. 133, no. 5, pp. 841–864, 1974. View at: Publisher Site | Google Scholar
  160. R. Carter III, S. N. Cheuvront, and M. N. Sawka, “A case report of idiosyncratic hyperthermia and review of U.S. Army heat stroke hospitalizations,” Journal of Sport Rehabilitation , vol. 16, no. 3, pp. 238–243, 2007. View at: Publisher Site | Google Scholar
  161. G. Keren, Y. Epstein, and A. Magazanik, “Temporary heat intolerance in a heatstroke patient,” Aviation, Space, and Environmental Medicine, vol. 52, no. 2, pp. 116-117, 1981. View at: Google Scholar
  162. P. Sithinamsuwan, K. Piyavechviratana, T. Kitthaweesin et al., “Exertional heatstroke: Early recognition and outcome with aggressive combined cooling - A 12-year experience,” Military Medicine, vol. 174, no. 5, pp. 496–502, 2009. View at: Publisher Site | Google Scholar
  163. L. E. Armstrong, R. W. Hubbard, J. P. DeLuca, and E. L. Christensen, “Signs and symptoms of heat exhaustion during strenuous exercise,” Annals of Sports Medicine, vol. 3, pp. 182–189, 1988. View at: Publisher Site | Google Scholar
  164. L. E. Armstrong, J. P. De Luca, and R. W. Hubbard, “Time course of recovery and heat acclimation ability of prior exertional heatstroke patients,” Medicine & Science in Sports & Exercise, vol. 22, no. 1, pp. 36–48, 1990. View at: Publisher Site | Google Scholar
  165. L. Leon and S. Dineen, “Prior viral infection increases heat stroke severity in mice,” The FASEB Journal, vol. 29, Supplement 1, 2015. View at: Google Scholar
  166. J. W. Gardner and J. A. Kark, “Clinical diagnosis, management, and surveillance of exertional heat illness, in Medical aspects of harsh environments,” in Offce of the Surgeon General , Department of the Army, United States of America, D. E. Lounsbury, R. F. Bellamy, and., and R. Zajtchuk, Eds., pp. 231–279, 2001. View at: Google Scholar
  167. D. J. Casa, J. Almquist, and S. Anderson, “Inter-association task force on exertional heat illnesses consensus statement,” NATA News, vol. 6, pp. 24–29, 2003. View at: Google Scholar
  168. S. Ghosh, R. Lertwattanarak, J. d. Garduno et al., “Elevated Muscle TLR4 Expression and Metabolic Endotoxemia in Human Aging,” The Journals of Gerontology. Series A, Biological Sciences and Medical Sciences, vol. 70, no. 2, pp. 232–246, 2015. View at: Publisher Site | Google Scholar
  169. F. Qian, X. Wang, L. Zhang et al., “Age-associated elevation in TLR5 leads to increased inflammatory responses in the elderly,” Aging Cell, vol. 11, no. 1, pp. 104–110, 2012. View at: Publisher Site | Google Scholar
  170. K. Rea, T. G. Dinan, and J. F. Cryan, “The microbiome: A key regulator of stress and neuroinflammation,” Neurobiology of Stress, vol. 4, pp. 23–33, 2016. View at: Publisher Site | Google Scholar
  171. E. Biagi, L. Nylund, M. Candela et al., “Through ageing, and beyond: Gut microbiota and inflammatory status in seniors and centenarians,” PLoS ONE, vol. 5, Articale ID e10667, 2010. View at: Publisher Site | Google Scholar
  172. D. A. Williamson, A. Lim, S. Wiles, S. A. Roberts, and J. T. Freeman, “Population-based incidence and comparative demographics of community-associated and healthcare-associated Escherichia coli bloodstream infection in Auckland, New Zealand, 2005 - 2011,” BMC Infectious Diseases, vol. 13, no. 1, article no. 385, 2013. View at: Publisher Site | Google Scholar
  173. R. M. Klevens, M. A. Morrison, J. Nadle et al., “Invasive methicillin-resistant Staphylococcus aureus infections in the United States,” Journal of the American Medical Association, vol. 298, no. 15, pp. 1763–1771, 2007. View at: Publisher Site | Google Scholar
  174. H. Bruunsgaard, P. Skinhøj, J. Qvist, and B. K. Pedersen, “Elderly humans show prolonged in vivo inflammatory activity during pneumococcal infections,” The Journal of Infectious Diseases, vol. 180, no. 2, pp. 551–554, 1999. View at: Publisher Site | Google Scholar
  175. S. Nakai, T. Itoh, and T. Morimoto, “Deaths from heat-stroke in Japan: 1968–1994,” International Journal of Biometerology, vol. 43, no. 3, pp. 124–127, 1999. View at: Publisher Site | Google Scholar
  176. M. I. Al-Khawashki, “Clinical presentation of 172 heat stroke cases seen at Mina and Arafat,” Heat stroke and temperature regulation, pp. 99–108, September 1982. View at: Google Scholar
  177. N. B. Strydom, “Age as a causal factor in heat stroke,” Journal of the Southern African Institute of Mining and Metallurgy, vol. 72, no. 4, pp. 112–114, 1971. View at: Google Scholar
  178. W. L. Kenney and J. L. Hodgson, “Heat tolerance, thermoregulation and ageing,” Sports Medicine, vol. 4, no. 6, pp. 446–456, 1987. View at: Publisher Site | Google Scholar
  179. A. J. Ryan, R.-T. Chang, and C. V. Gisolfi, “Gastrointestinal permeability following aspirin intake and prolonged running,” Medicine & Science in Sports & Exercise, vol. 28, no. 6, pp. 698–705, 1996. View at: Publisher Site | Google Scholar
  180. K. van Wijck, K. Lenaerts, J. Grootjans et al., “Physiology and pathophysiology of splanchnic hypoperfusion and intestinal injury during exercise: strategies for evaluation and prevention,” American Journal of Physiology-Gastrointestinal and Liver Physiology, vol. 303, no. 2, pp. G155–G168, 2012. View at: Publisher Site | Google Scholar
  181. G. P. Lambert, M. Boylan, J.-P. Laventure, A. Bull, and S. Lanspa, “Effect of aspirin and ibuprofen on GI permeability during exercise,” International Journal of Sports Medicine, vol. 28, no. 9, pp. 722–726, 2007. View at: Publisher Site | Google Scholar
  182. D. C. Nieman, D. A. Henson, C. L. Dumke et al., “Ibuprofen use, endotoxemia, inflammation, and plasma cytokines during ultramarathon competition,” Brain, Behavior, and Immunity, vol. 20, no. 6, pp. 578–584, 2006. View at: Publisher Site | Google Scholar
  183. G. D. Martich, R. L. Danner, M. Ceska, and A. F. Suffredini, “Detection of interleukin 8 and tumor necrosis factor in normal humans after intravenous endotoxin: The effect of antiinflammatory agents,” The Journal of Experimental Medicine, vol. 173, no. 4, pp. 1021–1024, 1991. View at: Publisher Site | Google Scholar
  184. G. A. Spinas, D. Bloesch, U. Keller, W. Zimmerli, and S. Cammisuli, “Pretreatment with ibuprofen augments circulating tumor necrosis factor-α, interleukin-6, and elastase during acute endotoxinemia,” The Journal of Infectious Diseases, vol. 163, no. 1, pp. 89–95, 1991. View at: Publisher Site | Google Scholar
  185. I. Bjarnason, B. Fehilly, P. Smethurst, I. S. Menzies, and A. J. Levi, “Importance of local versus systemic effects of non-steroidal anti-inflammatory drugs in increasing small intestinal permeability in man,” Gut, vol. 32, no. 3, pp. 275–277, 1991. View at: Publisher Site | Google Scholar
  186. K. D. Rainsford and M. W. Whitehouse, “Biochemical gastroprotection from acute ulceration induced by aspirin and related drugs,” Biochemical Pharmacology, vol. 29, no. 9, pp. 1281–1289, 1980. View at: Publisher Site | Google Scholar
  187. K. D. Rainsford, “Mechanisms of gastrointestinal ulceration from non-steroidal anti-inflammatory drugs: a basis for use and development of protective agents,” in Side-Effects of Anti-Inflammatory Drugs 3, vol. 5 of Inflammation and Drug Therapy Series, pp. 97–114, Springer Netherlands, Dordrecht, 1992. View at: Publisher Site | Google Scholar
  188. J. L. Madara, R. Moore, and S. Carlson, “Alteration of intestinal tight junction structure and permeability by cytoskeletal contraction,” American Journal of Physiology-Cell Physiology, vol. 253, no. 6, pp. C854–C861, 1987. View at: Publisher Site | Google Scholar
  189. M. Hayashi and M. Tomita, “Mechanistic analysis for drug permeation through intestinal membrane.,” Drug Metabolism and Pharmacokinetics, vol. 22, no. 2, pp. 67–77, 2007. View at: Publisher Site | Google Scholar
  190. T. Shimazaki, “Absorption-enhancing effects of sodium caprate and palmitoyl carnitine in rat and human colons,” Digestive Diseases and Sciences, vol. 43, pp. 641–645, 1998. View at: Google Scholar
  191. P. C. Wharam, D. B. Speedy, T. D. Noakes, J. M. D. Thompson, S. A. Reid, and L.-M. Holtzhausen, “NSAID use increases the risk of developing hyponatremia during an ironman triathlon,” Medicine & Science in Sports & Exercise, vol. 38, no. 4, pp. 618–622, 2006. View at: Publisher Site | Google Scholar
  192. T. Gorski, E. L. Cadore, S. S. Pinto et al., “Use of NSAIDs in triathletes: prevalence, level of awareness and reasons for use,” British Journal of Sports Medicine, vol. 45, no. 2, pp. 85–90, 2011. View at: Publisher Site | Google Scholar
  193. R. D. Smetanka, G. P. Lambert, R. Murray, D. Eddy, M. Horn, and C. V. Gisolfi, “Intestinal permeability in runners in the 1996 Chicago marathon,” Journal of the International Society of Sports Nutrition, vol. 9, no. 4, pp. 426–433, 1999. View at: Publisher Site | Google Scholar
  194. L. W. Bowen, “Fatal Hyperpyrexia with Antidepressant Drugs,” British Medical Journal, vol. 2, no. 5422, pp. 1465-1466, 1964. View at: Publisher Site | Google Scholar
  195. C. K. Dao, S. M. Nowinski, and E. M. Mills, “The heat is on: molecular mechanisms of drug-induced hyperthermia,” Temperature, vol. 1, no. 3, pp. 183–191, 2014. View at: Publisher Site | Google Scholar
  196. M. Martinez, L. Devenport, J. Saussy, and J. Martinez, “Drug-associated heat stroke,” Southern Medical Journal, vol. 95, no. 8, pp. 799–802, 2002. View at: Publisher Site | Google Scholar
  197. J. D. Watson, C. Ferguson, C. J. Hinds, R. Skinner, and J. H. Coakley, “Exertional heat stroke induced by amphetamine analogues: Does dantrolene have a place?” Anaesthesia, vol. 48, no. 12, pp. 1057–1060, 1993. View at: Publisher Site | Google Scholar
  198. J. F. Capacchione and S. M. Muldoon, “The relationship between exertional heat illness, exertional rhabdomyolysis, and malignant hyperthermia,” Anesthesia & Analgesia, vol. 109, no. 4, pp. 1065–1069, 2009. View at: Publisher Site | Google Scholar
  199. F. Loghmanee and M. Tobak, “Fatal malignant hyperthermia associated with recreational cocaine and ethanol abuse,” The American Journal of Forensic Medicine and Pathology, vol. 7, no. 3, pp. 246–248, 1986. View at: Publisher Site | Google Scholar
  200. C. M. Milroy, J. C. Clark, and A. R. W. Forrest, “Pathology of deaths associated with "ecstasy" and "eve" misuse,” Journal of Clinical Pathology, vol. 49, no. 2, pp. 149–153, 1996. View at: Publisher Site | Google Scholar
  201. J. P. Knochel and G. Reed, “Disorders of heat regulation,” in in Maxwell Kleeman's clinical disorders of fluid and electrolyte metabolism, pp. 1549–90, New York, McGraw Hill, 5th edition, 1994. View at: Google Scholar
  202. A. N. Stadnyk and J. D. Glezos, “Drug-induced heat stroke,” Canadian Medical Association Journal, vol. 128, no. 8, pp. 957–959, 1983. View at: Google Scholar
  203. C. W. Callaway and R. F. Clark, “Hyperthermia in psychostimulant overdose,” Annals of Emergency Medicine, vol. 24, no. 1, pp. 68–76, 1994. View at: Publisher Site | Google Scholar
  204. M. Carvalho, F. Carvalho, and M. L. Bastos, “Is hyperthermia the triggering factor for hepatotoxicity induced by 3,4-methylenedioxymethamphetamine (ecstasy)? An in vitro study using freshly isolated mouse hepatocytes,” Archives of Toxicology, vol. 74, no. 12, pp. 789–793, 2001. View at: Publisher Site | Google Scholar
  205. S. Kalaichandran, “Spontaneous haemoperitoneum in labour from ruptured utero-ovarian vessels,” Journal of the Royal Society of Medicine, vol. 84, no. 6, pp. 372-373, 1991. View at: Google Scholar
  206. M. D. Ginsberg, M. Hertzman, and W. W. Schmidt-Nowara, “Amphetamine intoxication with coagulopathy, hyperthermia, and reversible renal failure. A syndrome resembling heatstroke.,” Annals of Internal Medicine, vol. 73, no. 1, pp. 81–85, 1970. View at: Publisher Site | Google Scholar
  207. A. L. Jones and K. J. Simpson, “Review article: mechanisms and management of hepatotoxicity in ecstasy (MDMA) and amphetamine intoxications,” Alimentary Pharmacology & Therapeutics, vol. 13, no. 2, pp. 129–133, 1999. View at: Publisher Site | Google Scholar
  208. S. W. Flanagan, P. L. Moseley, and G. R. Buettner, “Increased flux of free radicals in cells subjected to hyperthermia: Detection by electron paramagnetic resonance spin trapping,” FEBS Letters, vol. 431, no. 2, pp. 285-286, 1998. View at: Publisher Site | Google Scholar
  209. R. H. Powers and A. Stadnicka, “Involvement of Xanthine Oxidase in Oxidative Stress and Iron Release during Hyperthermic Rat Liver Perfusion,” Cancer Research, vol. 52, no. 7, pp. 1699–1703, 1992. View at: Google Scholar
  210. C. Li and H.-M. Zhou, “The role of manganese superoxide dismutase in inflammation defense,” Enzyme Research, vol. 2011, Article ID 387176, 6 pages, 2011. View at: Publisher Site | Google Scholar
  211. N. Hanawa, M. Shinohara, B. Saberi, W. A. Gaarde, D. Han, and N. Kaplowitz, “Role of JNK translocation to mitochondria leading to inhibition of mitochondria bioenergetics in acetaminophen-induced liver injury,” The Journal of Biological Chemistry, vol. 283, no. 20, pp. 13565–13577, 2008. View at: Publisher Site | Google Scholar
  212. A. B. Reid, R. C. Kurten, S. S. McCullough, R. W. Brock, and J. A. Hinson, “Mechanisms of acetaminophen-induced hepatotoxicity: role of oxidative stress and mitochondrial permeability transition in freshly isolated mouse hepatocytes,” The Journal of Pharmacology and Experimental Therapeutics, vol. 312, no. 2, pp. 509–516, 2005. View at: Publisher Site | Google Scholar
  213. F. M. Ndikum-Moffor, T. R. Schoeb, and S. M. Roberts, “Liver toxicity from norcocaine nitroxide, an N-oxidative metabolite of cocaine,” The Journal of Pharmacology and Experimental Therapeutics, vol. 284, no. 1, pp. 413–419, 1998. View at: Google Scholar
  214. M. Carvalho, F. Remião, N. Milhazes et al., “The toxicity of N-methyl-α-methyldopamine to freshly isolated rat hepatocytes is prevented by ascorbic acid and N-acetylcysteine,” Toxicology, vol. 200, no. 2-3, pp. 193–203, 2004. View at: Publisher Site | Google Scholar
  215. O. S. El-Tawil, A. H. Abou-Hadeed, M. F. El-Bab, and A. A. Shalaby, “D-Amphetamine-induced cytotoxicity and oxidative stress in isolated rat hepatocytes,” Pathophysiology, vol. 18, no. 4, pp. 279–285, 2011. View at: Publisher Site | Google Scholar
  216. S. Samarghandian, R. Afshari, and T. Farkhondeh, “Effect of long-term treatment of morphine on enzymes, oxidative stress indices and antioxidant status in male rat liver,” International Journal of Clinical and Experimental Medicine, vol. 7, no. 5, pp. 1449–1453, 2014. View at: Google Scholar
  217. Y. Zhang, Q. Zheng, J. Pan, and R. Zheng, “Oxidative Damage of Biomolecules in Mouse Liver Induced by Morphine and Protected by Antioxidants,” Journal of Pharmacology and Toxicology, vol. 95, no. 2, pp. 53–58, 2004. View at: Publisher Site | Google Scholar
  218. S. Karch, in Pharmacokinetics and Pharmacodynamics of Abused Drugs, pp. 45–48, CRC Press, USA, 2007. View at: Publisher Site
  219. E. A. Johnson, A. A. Shvedova, E. Kisin, J. P. O'Callaghan, C. Kommineni, and D. B. Miller, “d-MDMA during vitamin E deficiency: Effects on dopaminergic neurotoxicity and hepatotoxicity,” Brain Research, vol. 933, no. 2, pp. 150–163, 2002. View at: Publisher Site | Google Scholar
  220. A. Eguchi, A. Wree, and A. E. Feldstein, “Biomarkers of liver cell death,” Journal of Hepatology, vol. 60, no. 5, pp. 1063–1074, 2014. View at: Publisher Site | Google Scholar
  221. P. E. Ganey and R. A. Roth, “Concurrent inflammation as a determinant of susceptibility to toxicity from xenobiotic agents,” Toxicology, vol. 169, no. 3, pp. 195–208, 2001. View at: Publisher Site | Google Scholar
  222. J. P. Nolan, “The role of intestinal endotoxin in liver injury: a long and evolving history,” Hepatology, vol. 52, no. 5, pp. 1829–1835, 2010. View at: Publisher Site | Google Scholar
  223. R. A. Roth, J. R. Harkema, J. P. Pestka, and P. E. Ganey, “Is exposure to bacterial endotoxin a determinant of susceptibility to intoxication from xenobiotic agents?” Toxicology and Applied Pharmacology, vol. 147, no. 2, pp. 300–311, 1997. View at: Publisher Site | Google Scholar
  224. J. P. Nolan and A. I. Leibowitz, “Endotoxin and the liver. III. Modification of acute carbon tetrachloride injury by polymyxin B-an antiendotoxin,” Gastroenterology, vol. 75, no. 3, pp. 445–449, 1978. View at: Google Scholar
  225. J. Meng, H. Yu, J. Ma et al., “Morphine Induces Bacterial Translocation in Mice by Compromising Intestinal Barrier Function in a TLR-Dependent Manner,” PLoS ONE, vol. 8, no. 1, Article ID e54040, 2013. View at: Publisher Site | Google Scholar
  226. F. M. Ocasio, Y. Jiang, S. D. House, and S. L. Chang, “Chronic morphine accelerates the progression of lipopolysaccharide-induced sepsis to septic shock,” Journal of Neuroimmunology, vol. 149, no. 1-2, pp. 90–100, 2004. View at: Publisher Site | Google Scholar
  227. K. M. Greeneltch, C. C. Haudenschild, A. D. Keegan, and Y. Shi, “The opioid antagonist naltrexone blocks acute endotoxic shock by inhibiting tumor necrosis factor-α production,” Brain, Behavior, and Immunity, vol. 18, no. 5, pp. 476–484, 2004. View at: Publisher Site | Google Scholar
  228. J. K. De Martini, D. J. Casa, R. Stearns et al., “Effectiveness of cold water immersion in the treatment of exertional heat stroke at the falmouth road race,” Medicine & Science in Sports & Exercise, vol. 47, no. 2, pp. 240–245, 2015. View at: Publisher Site | Google Scholar
  229. D. J. Casa, B. P. McDermott, E. C. Lee, S. W. Yeargin, L. E. Armstrong, and C. M. Maresh, “Cold water immersion: The gold standard for exertional heatstroke treatment,” Exercise and Sport Sciences Reviews, vol. 35, no. 3, pp. 141–149, 2007. View at: Publisher Site | Google Scholar
  230. A. Costrini, “Emergency treatment of exertional heatstroke and comparison of whole body cooling techniques,” Medicine & Science in Sports & Exercise, vol. 22, no. 1, pp. 15–18, 1990. View at: Google Scholar
  231. F. Jabr, “Probiotics Are No Panacea: Although certain bacteria help treat some gut disorders, they have no known benefits for healthy people,” Scientific American, vol. 317, no. 1, pp. 26-27, 2017. View at: Publisher Site | Google Scholar
  232. T. A. Oelschlaeger, “Mechanisms of probiotic actions—a review,” International Journal of Medical Microbiology, vol. 300, no. 1, pp. 57–62, 2010. View at: Publisher Site | Google Scholar
  233. M. X. Maldonado-Gómez, I. Martínez, F. Bottacini et al., “Stable Engraftment of Bifidobacterium longum AH1206 in the Human Gut Depends on Individualized Features of the Resident Microbiome,” Cell Host & Microbe, vol. 20, no. 4, pp. 515–526, 2016. View at: Publisher Site | Google Scholar
  234. M. Bermudez-Brito, J. Plaza-Díaz, S. Muñoz-Quezada, C. Gómez-Llorente, and A. Gil, “Probiotic mechanisms of action,” Annals of Nutrition and Metabolism, vol. 61, no. 2, pp. 160–174, 2012. View at: Publisher Site | Google Scholar
  235. E. Isolauri, P. V. Kirjavainen, and S. Salminen, “Probiotics: A role in the treatment of intestinal infection and inflammation?” Gut, vol. 50, no. 3, pp. iii54–iii59, 2002. View at: Publisher Site | Google Scholar
  236. S. Menard and M. Heyman, “Modulation of epithelial function and local immune system by probiotics: mechanisms involved,” Probiotics in Food Safety and Human Health, 341 pages, 2005. View at: Google Scholar
  237. P. Marteau, P. Seksik, and R. Jian, “Probiotics and intestinal health effects: a clinical perspective,” British Journal of Nutrition, vol. 88, no. S1, p. s51, 2002. View at: Publisher Site | Google Scholar
  238. L. V. McFarland and G. M. Elmer, “Properties of evidence-based probiotics for human health,” in Probiotics in food safety and human health, pp. 109–137, Marcel Dekker , Inc, New York, NJ, USA, 2005. View at: Google Scholar
  239. M. L. Ritchie and T. N. Romanuk, “A meta-analysis of probiotic efficacy for gastrointestinal diseases,” PLoS ONE, vol. 7, no. 4, Article ID e34938, 2012. View at: Publisher Site | Google Scholar
  240. K. Alfaleh and D. Bassler, “Probiotics for prevention of necrotizing enterocolitis in preterm infants.,” Cochrane Database of Systematic Reviews (Online), no. 1, p. CD005496, 2008. View at: Google Scholar
  241. N. Hoveyda, C. Heneghan, K. R. Mahtani, R. Perera, N. Roberts, and P. Glasziou, “A systematic review and meta-analysis: probiotics in the treatment of irritable bowel syndrome,” BMC Gastroenterology, vol. 9, article no. 15, 2009. View at: Publisher Site | Google Scholar
  242. M. G. Besselink et al., Ned Tijdschr Geneeskd, vol. 152, no. 12, pp. 685–696, 2008.
  243. P. A. Bron, M. Kleerebezem, R.-J. Brummer et al., “Can probiotics modulate human disease by impacting intestinal barrier function?” British Journal of Nutrition, vol. 117, no. 1, pp. 93–107, 2017. View at: Publisher Site | Google Scholar
  244. J.-M. Otte and D. K. Podolsky, “Functional modulation of enterocytes by gram-positive and gram-negative microorganisms,” American Journal of Physiology-Gastrointestinal and Liver Physiology, vol. 286, no. 4, pp. G613–G626, 2004. View at: Publisher Site | Google Scholar
  245. N. Parassol, M. Freitas, K. Thoreux, G. Dalmasso, R. Bourdet-Sicard, and P. Rampal, “Lactobacillus casei DN-114 001 inhibits the increase in paracellular permeability of enteropathogenic Escherichia coli-infected T84 cells,” Research in Microbiology, vol. 156, no. 2, pp. 256–262, 2005. View at: Publisher Site | Google Scholar
  246. A. A. Zyrek, C. Cichon, S. Helms, C. Enders, U. Sonnenborn, and M. A. Schmidt, “Molecular mechanisms underlying the probiotic effects of Escherichia coli Nissle 1917 involve ZO-2 and PKCzeta redistribution resulting in tight junction and epithelial barrier repair,” Cellular Microbiology, vol. 9, no. 3, pp. 804–816, 2007. View at: Publisher Site | Google Scholar
  247. N. A. Castillo, G. Perdigán, and A. De Moreno De Leblanc, “Oral administration of a probiotic Lactobacillus modulates cytokine production and TLR expression improving the immune response against Salmonella enterica serovar Typhimurium infection in mice,” BMC Microbiology, vol. 11, article no. 177, 2011. View at: Publisher Site | Google Scholar
  248. C. Gómez-Llorente, S. Muñoz, and A. Gil, “Role of Toll-like receptors in the development of immunotolerance mediated by probiotics,” Proceedings of the Nutrition Society, vol. 69, no. 3, pp. 381–389, 2010. View at: Publisher Site | Google Scholar
  249. M. Lamprecht, S. Bogner, G. Schippinger et al., “Probiotic supplementation affects markers of intestinal barrier, oxidation, and inflammation in trained men; a randomized, double-blinded, placebo-controlled trial,” Journal of the International Society of Sports Nutrition, vol. 9, article no. 45, 2012. View at: Publisher Site | Google Scholar
  250. J. D. Roberts, C. A. Suckling, G. Y. Peedle, J. A. Murphy, T. G. Dawkins, and M. G. Roberts, “An exploratory investigation of endotoxin levels in novice long distance triathletes,and the effects of a multi-strain probiotic/prebiotic,antioxidant intervention,” Nutrients, vol. 8, no. 11, article no. 733, 2016. View at: Publisher Site | Google Scholar
  251. H. V. Lin, A. Frassetto, E. J. Kowalik Jr. et al., “Butyrate and propionate protect against diet-induced obesity and regulate gut hormones via free fatty acid receptor 3-independent mechanisms,” PLoS ONE, vol. 7, no. 4, Article ID e35240, 2012. View at: Publisher Site | Google Scholar
  252. D. Ulluwishewa, R. C. Anderson, W. C. McNabb, P. J. Moughan, J. M. Wells, and N. C. Roy, “Regulation of tight junction permeability by intestinal bacteria and dietary components,” Journal of Nutrition, vol. 141, no. 5, pp. 769–776, 2011. View at: Publisher Site | Google Scholar
  253. L. A. David, C. F. Maurice, R. N. Carmody et al., “Diet rapidly and reproducibly alters the human gut microbiome,” Nature, vol. 505, no. 7484, pp. 559–563, 2014. View at: Publisher Site | Google Scholar
  254. R. A. Koeth, “Intestinal microbiota metabolism of L-carnitine, a nutrient in red meat, promotes atherosclerosis,” Nature Medicine, vol. 19, no. 5, pp. 576–585, 2013. View at: Google Scholar
  255. V. K. Ridaura, J. J. Faith, and F. E. Rey, “Gut microbiota from twins discordant for obesity modulate metabolism in mice,” Science, vol. 341, no. 6150, Article ID 1241214, 2013. View at: Google Scholar
  256. G. D. Wu, J. Chen, C. Hoffmann et al., “Linking long-term dietary patterns with gut microbial enterotypes,” Science, vol. 334, no. 6052, pp. 105–108, 2011. View at: Publisher Site | Google Scholar
  257. V. Mani, J. H. Hollis, and N. K. Gabler, “Dietary oil composition differentially modulates intestinal endotoxin transport and postprandial endotoxemia,” Journal of Nutrition and Metabolism, vol. 10, no. 1, article no. 6, 2013. View at: Publisher Site | Google Scholar
  258. R. Levy and E. Borenstein, “Metagenomic systems biology and metabolic modeling of the human microbiome: From species composition to community assembly rules,” Gut Microbes, vol. 5, no. 2, 2014. View at: Publisher Site | Google Scholar
  259. P. J. Turnbaugh, R. E. Ley, M. Hamady, C. M. Fraser-Liggett, R. Knight, and J. I. Gordon, “The human microbiome project,” Nature, vol. 449, no. 7164, pp. 804–810, 2007. View at: Publisher Site | Google Scholar
  260. P. J. Turnbaugh, V. K. Ridaura, J. J. Faith, F. E. Rey, R. Knight, and J. I. Gordon, “The effect of diet on the human gut microbiome: a metagenomic analysis in humanized gnotobiotic mice,” Science Translational Medicine, vol. 1, no. 6, p. 6ra14, 2009. View at: Publisher Site | Google Scholar
  261. K. M. Tuohy, C. Gougoulias, Q. Shen, G. Walton, F. Fava, and P. Ramnani, “Studying the human gut microbiota in the trans-omics era—focus on metagenomics and metabonomics,” Current Pharmaceutical Design, vol. 15, no. 13, pp. 1415–1427, 2009. View at: Publisher Site | Google Scholar
  262. D. R. Donohoe, N. Garge, X. Zhang et al., “The microbiome and butyrate regulate energy metabolism and autophagy in the mammalian colon,” Cell Metabolism, vol. 13, no. 5, pp. 517–526, 2011. View at: Publisher Site | Google Scholar
  263. B. W. Bolling, C.-Y. O. Chen, D. L. McKay, and J. B. Blumberg, “Tree nut phytochemicals: Composition, antioxidant capacity, bioactivity, impact factors. A systematic review of almonds, Brazils, cashews, hazelnuts, macadamias, pecans, pine nuts, pistachios and walnuts,” Nutrition Research Reviews, vol. 24, no. 2, pp. 244–275, 2011. View at: Publisher Site | Google Scholar
  264. P. Guilloteau, L. Martin, V. Eeckhaut, R. Ducatelle, R. Zabielski, and F. Van Immerseel, “From the gut to the peripheral tissues: The multiple effects of butyrate,” Nutrition Research Reviews, vol. 23, no. 2, pp. 366–384, 2010. View at: Publisher Site | Google Scholar
  265. H. M. Hamer, D. Jonkers, K. Venema, S. Vanhoutvin, F. J. Troost, and R.-J. Brummer, “Review article: the role of butyrate on colonic function,” Alimentary Pharmacology & Therapeutics, vol. 27, no. 2, pp. 104–119, 2008. View at: Publisher Site | Google Scholar
  266. Y. Wang, M. Yang, S.-G. Lee et al., “Diets high in total antioxidant capacity improve risk biomarkers of cardiovascular disease: A 9-month observational study among overweight/obese postmenopausal women,” European Journal of Nutrition, vol. 53, no. 6, pp. 1363–1369, 2014. View at: Publisher Site | Google Scholar
  267. X. Wu and A. G. Schauss, “Mitigation of inflammation with foods,” Journal of Agricultural and Food Chemistry, vol. 60, no. 27, pp. 6703–6717, 2012. View at: Publisher Site | Google Scholar
  268. R. Jiang, D. R. Jacobs Jr., E. Mayer-Davis et al., “Nut and seed consumption and inflammatory markers in the Multi-Ethnic Study of Atherosclerosis,” American Journal of Epidemiology, vol. 163, no. 3, pp. 222–231, 2006. View at: Publisher Site | Google Scholar
  269. L. M. Burke, “Re-Examining High-Fat Diets for Sports Performance: Did We Call the ‘Nail in the Coffin’ Too Soon?” Sports Medicine, vol. 45, pp. 33–49, 2015. View at: Publisher Site | Google Scholar
  270. D. L. Costill, W. M. Sherman, W. J. Fink, C. Maresh, M. Witten, and J. M. Miller, “The role of dietary carbohydrates in muscle glycogen resynthesis after strenuous running,” American Journal of Clinical Nutrition, vol. 34, no. 9, pp. 1831–1836, 1981. View at: Publisher Site | Google Scholar
  271. E. Franchini, C. J. Brito, and G. G. Artioli, “Weight loss in combat sports: Physiological, psychological and performance effects,” Journal of the International Society of Sports Nutrition, vol. 9, article no. 52, 2012. View at: Publisher Site | Google Scholar
  272. R. Maughan, “The athlete's diet: Nutritional goals and dietary strategies,” Proceedings of the Nutrition Society, vol. 61, no. 1, pp. 87–96, 2002. View at: Publisher Site | Google Scholar
  273. K. D. Tipton and R. R. Wolfe, “Protein and amino acids for athletes,” Journal of Sports Sciences, vol. 22, no. 1, pp. 65–79, 2004. View at: Publisher Site | Google Scholar
  274. J. S. Volek, T. Noakes, and S. D. Phinney, “Rethinking fat as a fuel for endurance exercise,” European Journal of Sport Science, vol. 15, no. 1, pp. 13–20, 2015. View at: Publisher Site | Google Scholar
  275. G. Sharon, N. Garg, J. Debelius, R. Knight, P. C. Dorrestein, and S. K. Mazmanian, “Specialized metabolites from the microbiome in health and disease,” Cell Metabolism, vol. 20, no. 5, pp. 719–730, 2014. View at: Publisher Site | Google Scholar
  276. P. Vitaglione, F. Morisco, N. Caporaso, and V. Fogliano, “Dietary antioxidant compounds and liver health,” Critical Reviews in Food Science and Nutrition, vol. 44, no. 7-8, pp. 575–586, 2004. View at: Publisher Site | Google Scholar
  277. J. M. Peake, K. Suzuki, and J. S. Coombes, “The influence of antioxidant supplementation on markers of inflammation and the relationship to oxidative stress after exercise,” The Journal of Nutritional Biochemistry, vol. 18, no. 6, pp. 357–371, 2007. View at: Publisher Site | Google Scholar
  278. M. L. Urso and P. M. Clarkson, “Oxidative stress, exercise, and antioxidant supplementation,” Toxicology, vol. 189, no. 1-2, pp. 41–54, 2003. View at: Publisher Site | Google Scholar
  279. G. Bartosz, “Reactive oxygen species: destroyers or messengers?” Biochemical Pharmacology, vol. 77, no. 8, pp. 1303–1315, 2009. View at: Publisher Site | Google Scholar
  280. A. Carr and B. Frei, “Does vitamin C act as a pro-oxidant under physiological conditions?” The FASEB Journal, vol. 13, no. 9, pp. 1007–1024, 1999. View at: Google Scholar
  281. A. C. Carr and B. Frei, “Toward a new recommended dietary allowance for vitamin C based on antioxidant and health effects in humans,” Am J Clin Nutr, vol. 69, no. 6, pp. 1086–107, 1999. View at: Google Scholar
  282. I. Gülçin, “Antioxidant activity of food constituents: an overview,” Archives of Toxicology, vol. 86, no. 3, pp. 345–391, 2012. View at: Publisher Site | Google Scholar
  283. J. Wu, A. Danielsson, and M. A. Zern, “Toxicity of hepatotoxins: New insights into mechanisms and therapy,” Expert Opinion on Investigational Drugs, vol. 8, no. 5, pp. 585–607, 1999. View at: Publisher Site | Google Scholar
  284. J. M. Gaziano, R. J. Glynn, W. G. Christen et al., “Vitamins E and C in the prevention of prostate and total cancer in men: the physicians' health study II randomized controlled trial,” The Journal of the American Medical Association, vol. 301, no. 1, pp. 52–62, 2009. View at: Publisher Site | Google Scholar
  285. S. M. Zhang, N. R. Cook, C. M. Albert, J. M. Gaziano, J. E. Buring, and J. E. Manson, “Effect of combined folic acid, vitamin B6, and vitamin B12 on cancer risk in women: a randomized trial,” Journal of the American Medical Association, vol. 300, no. 17, pp. 2012–2021, 2008. View at: Publisher Site | Google Scholar
  286. E. A. Klein, Vitamin E and the risk of prostate cancer: the Selenium and Vitamin E Cancer Prevention Trial (SELECT). JAMA, vol. 306, no. 14, pp. 1549–56, 2011.
  287. H. D. Sesso, J. E. Buring, W. G. Christen et al., “Vitamins E and C in the prevention of cardiovascular disease in men: the physicians' health study II randomized controlled trial,” Journal of the American Medical Association, vol. 300, no. 18, pp. 2123–2133, 2008. View at: Publisher Site | Google Scholar
  288. M. E. Törnwall, J. Virtamo, P. A. Korhonen et al., “Effect of α-tocopherol and β-carotene supplementation on coronary heart disease during the 6-year post-trial follow-up in the ATBC study,” European Heart Journal, vol. 25, no. 13, pp. 1171–1178, 2004. View at: Publisher Site | Google Scholar
  289. G. Bjelakovic, D. Nikolova, L. L. Gluud, R. G. Simonetti, and C. Gluud, “Mortality in randomized trials of antioxidant supplements for primary and secondary prevention: systematic review and meta-analysis,” The Journal of the American Medical Association, vol. 297, no. 8, pp. 842–857, 2007. View at: Publisher Site | Google Scholar
  290. B. Halliwell, “Free radicals and antioxidants: updating a personal view,” Nutrition Reviews, vol. 70, no. 5, pp. 257–265, 2012. View at: Publisher Site | Google Scholar
  291. B. Halliwell, “The antioxidant paradox: less paradoxical now?” British Journal of Clinical Pharmacology, vol. 75, no. 3, pp. 637–644, 2013. View at: Publisher Site | Google Scholar
  292. M. Rafieian-Kopaei, A. Baradaran, and M. Rafieian, “Oxidative stress and the paradoxical effects of antioxidants,” Journal of Research in Medical Sciences, vol. 18, no. 7, p. 628, 2013. View at: Google Scholar
  293. K. Dokladny, M. N. Zuhl, and P. L. Moseley, “Intestinal epithelial barrier function and tight junction proteins with heat and exercise,” Journal of Applied Physiology, vol. 120, no. 6, pp. 692–701, 2016. View at: Publisher Site | Google Scholar
  294. A. D. N. Soares, K. A. Costa, S. P. Wanner et al., “Dietary glutamine prevents the loss of intestinal barrier function and attenuates the increase in core body temperature induced by acute heat exposure,” British Journal of Nutrition, vol. 112, no. 10, pp. 1601–1610, 2014. View at: Publisher Site | Google Scholar
  295. K. D. Singleton and P. E. Wischmeyer, “Oral glutamine enhances heat shock protein expression and improves survival following hyperthermia,” Shock, vol. 25, no. 3, pp. 295–299, 2006. View at: Publisher Site | Google Scholar
  296. M. Zuhl, S. Schneider, K. Lanphere, C. Conn, K. Dokladny, and P. Moseley, “Exercise regulation of intestinal tight junction proteins,” British Journal of Sports Medicine, vol. 48, no. 12, pp. 980–986, 2014. View at: Publisher Site | Google Scholar
  297. K. A. Costa, A. D. Soares, and S. P. Wanner, “L-arginine supplementation prevents increases in intestinal permeability and bacterial translocation in male swiss mice subjected to physical exercise under environmental heat stress,” Journal of Nutrition, vol. 144, no. 2, pp. 218–223, 2014. View at: Publisher Site | Google Scholar
  298. A. L. Kau, P. P. Ahern, N. W. Griffin, A. L. Goodman, and J. I. Gordon, “Human nutrition, the gut microbiome and the immune system,” Nature, vol. 474, no. 7351, pp. 327–336, 2011. View at: Publisher Site | Google Scholar
  299. K. M. Maslowski and C. R. MacKay, “Diet, gut microbiota and immune responses,” Nature Immunology, vol. 12, no. 1, pp. 5–9, 2011. View at: Publisher Site | Google Scholar
  300. P. C. Calder and S. Kew, “The immune system: a target for functional foods?” British Journal of Nutrition, vol. 88, supplement 2, pp. S165–S176, 2002. View at: Publisher Site | Google Scholar
  301. M. Gleeson, D. C. Nieman, and B. K. Pedersen, “Exercise, nutrition and immune function,” Journal of Sports Sciences, vol. 22, no. 1, pp. 115–125, 2004. View at: Publisher Site | Google Scholar
  302. J. T. Venkatraman and D. R. Pendergast, “Effect of dietary intake on immune function in athletes,” Sports Medicine, vol. 32, no. 5, pp. 323–337, 2002. View at: Publisher Site | Google Scholar
  303. B. Sears, “Anti-inflammatory Diets,” Journal of the American College of Nutrition, vol. 34, pp. 14–21, 2015. View at: Publisher Site | Google Scholar
  304. P. C. Calder, “Polyunsaturated fatty acids, inflammation, and immunity,” Lipids, vol. 36, no. 9, pp. 1007–1024, 2001. View at: Publisher Site | Google Scholar
  305. E. Peters, “Exercise, Immunology and Upper Respiratory Tract Infections,” International Journal of Sports Medicine, vol. 18, no. S 1, pp. S69–S77, 1997. View at: Publisher Site | Google Scholar
  306. E. W. Peterson and B. K. Pedersen, “Exercise and Immune Function - Effect of Nutrition,” Nutrition and Immune Function, Chapter 16, 347 pages, 2002. View at: Google Scholar
  307. V. Purohit, J. C. Bode, C. Bode et al., “Alcohol, intestinal bacterial growth, intestinal permeability to endotoxin, and medical consequences: summary of a symposium,” Alcohol, vol. 42, no. 5, pp. 349–361, 2008. View at: Publisher Site | Google Scholar
  308. ADA, “Position of the American Dietetic Association: Health implications of dietary fiber,” Journal of the American Dietetic Association, vol. 102, no. 7, pp. 993–1000, 2002. View at: Publisher Site | Google Scholar
  309. FAO and WHO, “Vitamin and mineral requirements in human nutrition,” 2005. View at: Google Scholar
  310. C. W. C. Kendall, A. Esfahani, and D. J. A. Jenkins, “The link between dietary fibre and human health,” Food Hydrocolloids, vol. 24, no. 1, pp. 42–48, 2010. View at: Publisher Site | Google Scholar
  311. J. G. Sobiecki, P. N. Appleby, K. E. Bradbury, and T. J. Key, “High compliance with dietary recommendations in a cohort of meat eaters, fish eaters, vegetarians, and vegans: Results from the European Prospective Investigation into Cancer and Nutrition-Oxford study,” Nutrition Research, vol. 36, no. 5, pp. 464–477, 2016. View at: Publisher Site | Google Scholar
  312. A. K. Benson, “Individuality in gut microbiota composition is a complex polygenic trait shaped by multiple environmental and host genetic factors,” Proc Natl Acad Sci U S A, vol. 107, no. 44, pp. 18933–18938, 2010. View at: Google Scholar
  313. J. K. Goodrich, J. L. Waters, A. C. Poole et al., “Human genetics shape the gut microbiome,” Cell, vol. 159, no. 4, pp. 789–799, 2014. View at: Publisher Site | Google Scholar
  314. A. Spor, O. Koren, and R. Ley, “Unravelling the effects of the environment and host genotype on the gut microbiome,” Nature Reviews Microbiology, vol. 9, no. 4, pp. 279–290, 2011. View at: Publisher Site | Google Scholar
  315. C. Feterowski, K. Emmanuilidis, T. Miethke et al., “Effects of functional toll-like receptor-4 mutations on the immune response to human and experimental sepsis,” The Journal of Immunology, vol. 109, no. 3, pp. 426–431, 2003. View at: Publisher Site | Google Scholar
  316. L. V. Hooper, D. R. Littman, and A. J. Macpherson, “Interactions between the microbiota and the immune system,” Science, vol. 336, no. 6086, pp. 1268–1273, 2012. View at: Publisher Site | Google Scholar
  317. Z. Xu and R. Knight, “Dietary effects on human gut microbiome diversity,” British Journal of Nutrition, vol. 113, pp. S1–S5, 2015. View at: Publisher Site | Google Scholar
  318. E. G. Zoetendal, A. D. L. Akkermans, W. M. Akkermans-van Vliet, J. A. G. M. De Visser, and W. M. De Vos, “The host genotype affects the bacterial community in the human gastrointestinal tract,” Microbial Ecology in Health and Disease, vol. 13, no. 3, pp. 129–134, 2001. View at: Publisher Site | Google Scholar
  319. C. Huttenhower, D. Gevers, R. Knight et al., “Structure, function and diversity of the healthy human microbiome,” Nature, vol. 486, no. 7402, pp. 207–214, 2012. View at: Publisher Site | Google Scholar
  320. E. Holmes, J. V. Li, J. R. Marchesi, and J. K. Nicholson, “Gut microbiota composition and activity in relation to host metabolic phenotype and disease risk,” Cell Metabolism, vol. 16, no. 5, pp. 559–564, 2012. View at: Publisher Site | Google Scholar
  321. S. T. O'Dwyer, H. R. Michie, T. R. Ziegler, A. Revhaug, R. J. Smith, and D. W. Wilmore, “A Single Dose of Endotoxin Increases Intestinal Permeability in Healthy Humans,” JAMA Surgery, vol. 123, no. 12, pp. 1459–1464, 1988. View at: Publisher Site | Google Scholar
  322. D. J. Casa, L. E. Armstrong, G. P. Kenny, F. G. O'Connor, and R. A. Huggins, “Exertional heat stroke: New concepts regarding cause and care,” Current Sports Medicine Reports, vol. 11, no. 3, pp. 115–123, 2012. View at: Publisher Site | Google Scholar
  323. M. Arumugam, J. Raes, E. Pelletier et al., “Enterotypes of the human gut microbiome,” Nature, vol. 473, no. 7346, pp. 174–180, 2011. View at: Publisher Site | Google Scholar
  324. M. Blaut and T. Clavel, “Metabolic Diversity of the Intestinal Microbiota: Implications for Health and Disease,” Journal of Nutrition, vol. 137, no. 3, pp. 751S–755S, 2007. View at: Publisher Site | Google Scholar
  325. P. H. Bradley and K. S. Pollard, “Proteobacteria explain significant functional variability in the human gut microbiome,” Microbiome, vol. 5, no. 1, article no. 36, 2017. View at: Publisher Site | Google Scholar
  326. J. J. Faith, J. L. Guruge, M. Charbonneau et al., “The long-term stability of the human gut microbiota,” Science, vol. 341, no. 6141, Article ID 1237439, 2013. View at: Publisher Site | Google Scholar
  327. S. Hu, Y. Wang, L. Lichtenstein et al., “Regional differences in colonic mucosa-associated microbiota determine the physiological expression of host heat shock proteins,” American Journal of Physiology-Gastrointestinal and Liver Physiology, vol. 299, no. 6, pp. G1266–G1275, 2010. View at: Publisher Site | Google Scholar
  328. M. G. Espey, “Role of oxygen gradients in shaping redox relationships between the human intestine and its microbiota,” Free Radical Biology & Medicine, vol. 55, pp. 130–140, 2013. View at: Publisher Site | Google Scholar
  329. P. Marteau, P. Pochart, J. Doré, C. Béra-Maillet, A. Bernalier, and G. Corthier, “Comparative Study of Bacterial Groups within the Human Cecal and Fecal Microbiota,” Applied and Environmental Microbiology, vol. 67, no. 10, pp. 4939–4942, 2001. View at: Publisher Site | Google Scholar
  330. A. M. Mowat and W. W. Agace, “Regional specialization within the intestinal immune system,” Nature Reviews Immunology, vol. 14, no. 10, pp. 667–685, 2014. View at: Publisher Site | Google Scholar
  331. P. Dharmani, V. Srivastava, V. Kissoon-Singh, and K. Chadee, “Role of intestinal mucins in innate host defense mechanisms against pathogens,” Journal of Innate Immunity, vol. 1, no. 2, pp. 123–135, 2009. View at: Publisher Site | Google Scholar
  332. B. V. Jones, M. Begley, C. Hill, C. G. M. Gahan, and J. R. Marchesi, “Functional and comparative metagenomic analysis of bile salt hydrolase activity in the human gut microbiome,” Proceedings of the National Acadamy of Sciences of the United States of America, vol. 105, no. 36, pp. 13580–13585, 2008. View at: Publisher Site | Google Scholar
  333. Y. Wang and L. H. Kasper, “The role of microbiome in central nervous system disorders,” Brain, Behavior, and Immunity, vol. 38, pp. 1–12, 2014. View at: Publisher Site | Google Scholar
  334. G. P. Donaldson, S. M. Lee, and S. K. Mazmanian, “Gut biogeography of the bacterial microbiota,” Nature Reviews Microbiology, vol. 14, no. 1, pp. 20–32, 2015. View at: Publisher Site | Google Scholar
  335. Y. Belkaid and S. Naik, “Compartmentalized and systemic control of tissue immunity by commensals,” Nature Immunology, vol. 14, no. 7, pp. 646–653, 2013. View at: Publisher Site | Google Scholar
  336. F. J. Gennari and W. J. Weise, “Acid-base disturbances in gastrointestinal disease,” Clinical Journal of the American Society of Nephrology, vol. 3, no. 6, pp. 1861–1868, 2008. View at: Publisher Site | Google Scholar
  337. P. L. Moseley, C. Gapen, E. S. Wallen, M. E. Walter, and M. W. Peterson, “Thermal stress induces epithelial permeability,” American Journal of Physiology-Cell Physiology, vol. 267, no. 2, pp. C425–C434, 1994. View at: Publisher Site | Google Scholar
  338. J. A. Otte, E. Oostveen, R. H. Geelkerken, A. B. J. Groeneveld, and J. J. Kolkman, “Exercise induces gastric ischemia in healthy volunteers: a tonometry study,” Journal of Applied Physiology, vol. 91, no. 2, pp. 866–871, 2001. View at: Publisher Site | Google Scholar
  339. D. M. Hall, K. R. Baumgardner, T. D. Oberley, and C. V. Gisolfi, “Splanchnic tissues undergo hypoxic stress during whole body hyperthermia,” American Journal of Physiology-Gastrointestinal and Liver Physiology, vol. 276, no. 5, pp. G1195–G1203, 1999. View at: Publisher Site | Google Scholar
  340. D. A. Hill and D. Artis, “Intestinal bacteria and the regulation of immune cell homeostasis,” Annual Review of Immunology, vol. 28, pp. 623–667, 2010. View at: Publisher Site | Google Scholar
  341. D. Festi, R. Schiumerini, L. H. Eusebi, G. Marasco, M. Taddia, and A. Colecchia, “Gut microbiota and metabolic syndrome,” World Journal of Gastroenterology, vol. 20, no. 43, pp. 16079–16094, 2014. View at: Publisher Site | Google Scholar
  342. F. D'Aversa, A. Tortora, G. Ianiro, F. R. Ponziani, B. E. Annicchiarico, and A. Gasbarrini, “Gut microbiota and metabolic syndrome,” Internal and Emergency Medicine, vol. 8, no. 1, pp. 11–15, 2013. View at: Publisher Site | Google Scholar
  343. N. Mach and D. Fuster-Botella, “Endurance exercise and gut microbiota: A review,” Journal of Sport and Health Science, vol. 6, no. 2, pp. 179–197, 2017. View at: Publisher Site | Google Scholar
  344. G. P. Lambert, “Stress-induced gastrointestinal barrier dysfunction and its inflammatory effects,” Journal of Animal Science, vol. 87, no. 14, supplement, pp. E101–E108, 2009. View at: Publisher Site | Google Scholar
  345. J. E. Dematte, K. O'Mara, J. Buescher et al., “Near-fatal heat stroke during the 1995 heat wave in Chicago,” Annals of Internal Medicine, vol. 129, no. 3, pp. 173–181, 1998. View at: Publisher Site | Google Scholar
  346. A. C. Eichler, A. S. McFee, and H. D. Root, “Heat stroke,” The American Journal of Surgery, vol. 118, no. 6, pp. 855–863, 1969. View at: Publisher Site | Google Scholar
  347. X. Wu, L. Gu, J. Holden et al., “Development of a database for total antioxidant capacity in foods: A preliminary study,” Journal of Food Composition and Analysis, vol. 17, no. 3-4, pp. 407–422, 2004. View at: Publisher Site | Google Scholar
  348. D. S. Kelley, Y. Adkins, A. Reddy, L. R. Woodhouse, B. E. Mackey, and K. L. Erickson, “Sweet bing cherries lower circulating concentrations of markers for chronic inflammatory diseases in healthy humans,” Journal of Nutrition, vol. 143, no. 3, pp. 340–344, 2013. View at: Publisher Site | Google Scholar
  349. M. J. Gosalbes, A. Durbán, M. Pignatelli et al., “Metatranscriptomic approach to analyze the functional human gut microbiota,” PLoS ONE, vol. 6, no. 3, Article ID e17447, 2011. View at: Publisher Site | Google Scholar

Copyright © 2018 Lawrence E. Armstrong et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

More related articles

3164 Views | 985 Downloads | 8 Citations
 PDF Download Citation Citation
 Download other formatsMore
 Order printed copiesOrder

Related articles

We are committed to sharing findings related to COVID-19 as quickly as possible. We will be providing unlimited waivers of publication charges for accepted research articles as well as case reports and case series related to COVID-19. Review articles are excluded from this waiver policy. Sign up here as a reviewer to help fast-track new submissions.